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CHAPTER 1 
TREATMENT OF CHOLESTATIC LIVER DISEASES: 
THE STATE OFTHE ART IN 1994 
Hubert JF van Hoogstraten, Solko W Schalm 
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1 Cholestatic liver diseases 
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chro-
nic cholestatic liver diseases, biochemically characterised by an elevated serum 
bilirubin, alkaline phosphatase (APh) and y-glutamyl transferase (y-GT). Although 
PBC and PSC have their own distinctive clinical, immunological, radiological and 
histological features, both diseases show a necro-inflammatory process, predomi-
nantly confined to the bile ducts within the portal tracts. In most patients the disea-
se gradually progresses and may lead to cirrhosis and liver failure. Transplantation 
may then be the only therapeutic option left. 
1.1 Primary Biliary Cirrhosis 
Introduction 
In 1851, Addison and Gull described the first case of skin xanthomas in combina-
tion with severe jaundice (1). Since then, several reports have been published 
about this syndrome, which became known as xanthomateous biliary cirrhosis. In 
1950, Ahrens et al proposed the term primary biliary cirrhosis (2), which is mislea-
ding because cirrhosis is only present in end-stage disease; primary immune-cho-
langitis might be a more appropriate name (3, 4). 
The reported prevalence of PBC varies greatly between different populations, ran-
ging from 5 to more than 300 cases per million people, and seems to be increasing 
(5-10). According to the European Liver Transplantation Registration, in 1998, PBC 
was the third leading indication for liver transplantation in Europe. 
Clinical features and natural course 
Patients, 70% of whom are middle aged women, typically present with pruritus and 
fatigue. Other complaints include upper right abdominal pain, arthralgia, dry eyes 
and mouth and the presence of xanthomas. Because of increased biochemical 
screening during treatment for other diseases and because of an increased aware-
ness, more and more patients present in an asymptomatic state. Although dispu-
ted, PBC is frequently associated with autoimmune diseases such as keratocon-
junctivitis sicca, polyarthritis, scleroderma and autoimmune thyroiditis (11, 12). IgM 
and cholesterol levels are often elevated (13, 14). However, an elevated serum 
cholesterol does not seem to lead to an increased mortality of cardiovascular disea-
se (15). Pivotal in the diagnosis of PBC is the presence of antimitochondrial anti-
bodies (AMA) in serum, which are present in 90%-95% of patients (16). AMA are 
directed against a series of intra-mitochondrial proteins, in particular the 2-oxo acid 
dehydrogenase complexes, including the dihydrolipoylacetyltransferase component 
of the pyruvate dehydrogenase complex E2, the branched-chain 2-oxo acid dehy-
drogenase complex E2, and the 2-oxoglutarate dehydrogenase complex E2. AMA 
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are found in serum and in bile (17-19). The role of AMA in the aetiology of PBC is 
still debated (see below). 
The progression of PBC is slow. In patients without any symptoms, survival has 
been reported to be equal to the normal population (20). Others, however, have 
found a decreased survival in asymptomatic patients (21, 22). 
Histomorphology 
Histologically, PBC is characterised by a non-suppurative destructive cholangitis or 
a granulomatous cholangitis. Four histological stages have been identified by 
Scheuer et aI., which were later modified by Ludwig et aI., and are now generally 
used (4, 23). In stage I, florid bile duct lesions and necrotic bile ducts with shrun-
ken and vacuolated epithelial cells are seen. Surrounding the bile ducts, a cellular 
infiltrate consisting of lymphocy1es, plasma cells, histiocy1es, eosinophils and giant 
cells is noticed. Non-caseating granulomas are commonly observed. In stage II, 
the lesions are not confined to the portal tracts but start to infiltrate in the surroun-
ding parenchyma with destruction of the limiting plate and piecemeal necrosis. A 
gradual loss of bile ducts occurs with consequent ductular proliferation. Stage III 
shows progression of fibrosis with the formation of porto-portal septa. In stage IV 
the disease has progressed to cirrhosis. 
Pathogenesis 
Although direct proof is lacking, there is growing evidence that PBC is an immune 
mediated disease. Indirect proof lies in the presence of auto-antibodies, particularly 
AMA, which are present in 90%-95% of patients (24); an elevated IgM; a strong 
association with other autoimmune diseases (12); and numerous defects in cellular 
and humoral immunological regulation mechanisms (table 1) (25). 
Genetic factors may also playa role. Although data are few, PBC has an estimated 
prevalence ranging from 2.4% to 14.9% in family members (26, 27). Furthermore, an 
association with HLA-DR2, 3,4 and 8 has been reported in various populations (28). 
Treatment 
At the end of 1994, no cure for PBC was available. The effects of a number of the-
rapeutic agents were assessed, which will be discussed below. 
Ursodeoxycholic acid 
In 1981, Leuschner et al were the first to report about the beneficial effects of 
UDCA in patients with chronic active hepatitis and gallstones (29). This was fol-
lowed in 1987 by Poupon et al reporting uncontrolled data about an improvement 
in liver function tests and pruritus in PBC patients treated with UDCA (30). 
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Table 1: Reported immunological abnormalities in PBC (25). 
Presence of AMA and other antibodies 
Skin test anergy 
Increased serum IgG 
Increased serum IgM 
Increased complement activation and turn-over 
Circulating-immune-complex-like activity 
Suppresser T lymphocyte dysfunction 
Decreased mixed lymphocyte response 
Circulating activated B lymphocytes 
Alteration of T cell subsets 
Cytotoxic lymphocytes infiltrating bile ducts epithelium cells 
Expression of class II MHC antigens by bile duct epithelium 
Decreased Kupffer cell function 
Table 2: Major clinical trials in PBC with UDCA mono-therapy until the end of 1994. 
Results 
year design follow-up n biochemistry histology survival 
Leuschner 1989 RCT 9 months .20 improved trend n.a. 
Battezzati 1993 RCT 6 months 88 improved n.a. n.a. 
Poupon 1994 RCT 4 years 145 improved n.a. improved 
Lindor 1994 RCT 2 years 180 improved n.s. n.s. 
Heathcote 1994 RCT 2 years 222 improved trend n.s. 
Turner 1994 RCT 2 years 64 improved n.s. n.S. 
RCT: randomised controlled trial; improved: significantly improved; trend: improvements 
were reported, which were not significant; n.a.: not assessed; n.s.: not significant. 
UDCA did not clearly improve symptoms in any of the trials. 
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Subsequently, a number of randomised controlled trials with UDCA in PBC were 
performed (31-35)(table 2). In all studies significant improvements in serum liver 
function tests were found whereas effects of UDCA on histology were inconsistent. 
Effects on pruritus and fatigue were absent. In the French study, UDCA significant-
ly, although modestly, improved transplantation free survival (32). At the end of 
1994, it was generally accepted that UDCA was the treatment of choice for 
patients with PBC. 
UDCA (3a, 7b-dihydroxy-5b cholan-24-oic acid) was firstly isolated from bile of the 
Chinese black bear and was named after this species (36). In healthy subjects, it is 
only present in small quantities of up to 5 mol% in the bile acid pool (37-39). 
Various mechanisms of action of UDCA in cholestatic liver diseases have been 
suggested: membrano-protection, induction of increased bile flow and immuno-
modulation (40). 
Hydrophobicity and the membrano-disruptive properties of bile acids decrease in 
the following order: Deoxycholate> chenodeoxycholate > cholate > ursodeoxycho-
late> p-muricholate (41). In isolated rat (42) and human hepatocy1es (43, 44) and 
in a rat model of cholestasis (45), it has been shown that UDCA protects against 
the toxic effects of more lipophilic bile acids. Furthermore, UDCA stabilises isolated 
red blood cell, hepatocy1e and artificial membranes (46, 47). Thus, the disruption of 
the canalicular membrane by the retention of more lipophilic endogenous bile acids 
in cholestatic liver disease might be counteracted by UDCA. 
There is growing evidence that conjugates of UDCA stimulate bile flow. It has been 
shown that tauro-ursodeoxycholate stimulates bile flow in isolated rat livers after 
bile duct ligation (48). In vivo, increased phospholipid and endogenous bile acid 
excretion has been observed in PSC patients treated with UDCA (49). UDCA may 
be excreted in bile in the non-conjugated state, which can quickly be converted 
into the protonated form in the small bile ducts. This is accompanied by secretion 
of bile that is rich in bicarbonate. Next, the protonated form of UDCA will be absor-
bed in the duct, transported back to the liver cell and again be excreted in bile. This 
process of "cholehepatic shunt" leads to a choleresis, rich in bicarbonate. Whether 
this process plays a part in man has not been demonstrated so far. It has clearly 
been established in animals (50). 
Bile salts, including UDCA, are strong suppressers of lymphocy1e proliferation in vitro 
(51-54), probably by a direct toxic effect./n vivo, UDCA reduces the aberrant expres-
sion of class I major histocompatibility complex molecules on hepatocy1es (55), 
which might be secondary to diminished cholestasis and immunological stimulation. 
Other drugs 
At the end of 1994, a variety of immuno-suppressive (56-66), cupruretic (67-72), 
anti-fibrotic (73-79) and other drugs (80-82) has been evaluated in PBC (table 2). 
Although improvements in liver function tests together with histological improve-
ments were noted especially with immunosuppressive drugs, effects on symptoms 
and survival have been disappointing, which might be explained by insufficient 
patient numbers and a too short follow-up period. 
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Table 3: Major randomised clinical trials with other drugs than UDCA or in combination with UDCA in 
pse until the end of 1994. 
Results 
design duration n biochemistry histology survival symptoms 
Prednis(ol)on 
Mitchison (56) RCT 3 years 36 improved stable n.s. improved 
Colchicine 
Bodenheimer (73) RCT 33 months 57 improved n.S. n.s. n.s. 
Kaplan (74) RCT 2 years 60 improved n.s. trend n.S. 
Cyclosporin A 
Minuk (60) RCT 1 years 12 improved n.S. n.a. n.s 
Wiesner (61) RCT 1 years 29 improved trend trend trend 
Lombard (62) RCT 2.5 years 349 improved n.S. improved improved 
Malotilate 
Multi centre (81) RCT 28 months 101 improved +10 n,S. n.S. 
Chlorambucil 
Hoofnagle (63) RCT 52 months 24 improved +10 n.s. n.a. 
Thalidomide 
McCormick (82) RCT 6 months 18 n.s. n.S. n.a. n.s. 
D~Peniciliamine 
Dickson (68) RCT 5 years 227 n.s. n.s. n.s. n.s. 
Matloff (69) RCT 2 years 52 n.s. n.s n.s n.s. 
Epstein (70) RCT 33 months 87 improved +/0 improved n.a. 
Taal (71) RCT 1 year 24 n.s. n.s. n.a. n.s. 
Neuberger (72) RCT 2 years 189 n.s. n.s. n.s. n.a. 
Azathioprine 
Christensen (156) RCT ± 5 years 248 n.a. n.a. improved n.a. 
Heathcote (59) RCT ± 2.5 years 55 n.s. n.s. n.s. n.s. 
RCT: randomised controlled trial; improved: significantly improved; n.s.: not significant; trend: impro~ 
vements were reported, which were not significant; +/0: improvement in markers of inflammation but 
no change in level of fibrosis; n.a.: not assessed. 
Biochemical remission 
In 1994, studies became available showing that treatment with UDCA leads to bio-
chemical remission in 15-20% of patients with PSC (83, 84). As in other autoimmu-
ne diseases, e.g. autoimmune hepatitis, biochemical remission of the disease 
could be indicative of a subsequently favourable long-term outcome. The prognos-
tic significance of biochemical remission, however, was not determined. Further-
more, no data were available concerning the relative importance as a prognostic 
factor of each biochemical parameter comprising biochemical remission. The prog-
nostic value of bilirubin in untreated PSC patients was already established (20, 21, 
85). Whether serum bilirubin continued to be of prognostic value in PSC patients 
treated with UDCA was still to be assessed. 
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1.2 Primary Sclerosing cholangitis 
A French surgeon described the first case of PSC in 1924 (86), followed in 1925 by 
similar observations of strongly icteric patients, complaining of severe pruritus, in 
whom an enlarged fibrotic and obliterated bile duct was found during operation (87, 
88). Before the introduction of endoscopic retrograde cholangiography (ERC), 
which is pivotal in the diagnosis, only few cases were reported. Since this techni-
que has become available, the reported prevalence is seen to be rising (89, 90); 
increased awareness may also playa role. The true prevalence of the disease is 
unknown, but estimates range from 20-70 cases per million based on a prevalence 
of PSC in 2.5%-7.5% of patients with ulcerative colitis. It is the fourth leading indi-
cation for liver transplantation in adults in the United States (91). 
Clinical features and natural course 
The majority of patients (approximately 65%) are men with a mean age at diagno-
sis of about 40 years. Patients may be asymptomatic at presentation. The majority 
of patients (80%), however, present with symptoms including fatigue, pruritus, 
jaundice and right upper quadrant abdominal pain. 70-80% of patients are diagno-
sed with concomitant inflammatory bowel disease (IBD) of which 90% is classified 
as ulcerative colitis (UC) (92-96). Its is still debated whether PSC is an indepen-
dent risk factor for the development of colorectal neoplasm in patients with PSC 
and UC (97, 98). 
Perinuclear antineutrophil cytoplasmic antibodies (pANCA), which are antibodies 
against myeloperoxidase and elastase located close to the cell nucleus of poly-
morphonuclear neutrophil leukocytes after ethanol fixation (99), are found in about 
70% of patients with PSC (100-102) and in approximately 25% of their relatives 
(103). 
Although characteristic histological lesions (see below) may be the only indication 
of PSC, leading to the diagnosis of "small-duct PSC" (104, 105); in about 90% of 
cases, typical cholangiographic lesions are found. Diffuse multifocal strictures 
involving both the intrahepatic and eX1rahepatic ducts are the most common fin-
dings. Strictures are usually short, with normal or dilated segments in-between, 
leading to a characteristic "beaded" appearance. Sometimes diverticula are seen. 
The pancreatic duct may be involved as well. With more advanced disease, long 
confluent strictures occur (106-108). Apart from diffuse irregularities, a so-called 
single "dominant stricture" may be present. 
Transplantation free survival of PSC patients is around 12-17 years from the time 
of diagnosis (92, 94-96). In a-symptomatic patients, the prognosis is better, but still 
worse than in age matched controls (109). An important factor influencing the 
prognosis is the increased risk of cholangiocarcinoma, which has an incidence 
between 10 and 15% in PSC patients (91). The incidence of cholangiocarcinoma 
rises with increasing disease severity (110). 
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Histomorphology 
Although only found in a minority of cases, the characteristic histological lesion in 
PSG is a fibrous-obliterative cholangitis, a combination of cholangitis with so-called 
"onion-skin" fibrosis, consisting of concentric periductal layers of collagen fibres 
(104). Furthermore, bile-duct proliferation, periductal inflammation, ductal oblitera-
tion and loss of bile ducts may be seen. The ductal changes are associated with 
portal oedema, mild portal and periportal inflammation, cholestasis and, conse-
quently, periportal copper accumulation. Eventually fibrosis and cirrhosis occur. 
Four stages are identified: In stage 1, lesions are confined to the portal tracts; in 
stage 2, periportal fibrosis or inflammation are found in the portal and periportal 
areas; in stage 3, septal fibrosis, bridging necrosis or both occur and in stage 4 cir-
rhosis is found (111). The lesions are not equally distributed throughout the liver 
and sampling error might occur (112). 
Aetiology 
The aetiology of PSG is largely unknown, although a number of immunologic (113) 
and non-immunological (114) factors have been considered (91, 115). Because 
ulcerative colitis is present in the majority of patients, it has been suggested that 
portal bacteremia or absorption of various toxins from the inflamed colon may play 
a role in the pathogenesis of PSG. However, as PSG may well develop in the 
absence of ulcerative colitis or after proctocolectomy, it is now generally believed 
that bacterial products are not likely to be of major importance in the pathogenesis 
of PSG. As in other autoimmune diseases, it has been suggested that viral infec-
tion -especially GMV- may trigger an autoimmune process through cross-reactivity 
between viral and liver-derived antigens. Arterial insufficiency, e.g. after transplan-
tation or after hepatic artery infusion of fluorodeoxyuridine as a treatment for liver 
metastases, may cause cholangiographic findings similar of PSG. However, in 
patients with PSG evidence of vascular abnormalities is generally absent. 
PSG may be an immune mediated disease (113) and a number of humoral and 
cellular abnormalities have been observed. A close association has been found 
between PSG and HLA-B8, HLA-Dr3 or HLA-Drw52a phenotype (116-118). In the 
majority of PSG patients and in patients with ulcerative colitis (99, 119) or autoim-
mune hepatitis (120), autoantibodies, particularly pANGA, are present, which may 
imply a common autoimmune mediated pathogenesis. Furthermore, the simultane-
ous presence of AIH and PSG has been described in children (121) and in a num-
ber of adults (122-125). 
Finally, a number of other immune abnormalities have been observed, such as an 
increased GD4!GD8 T-cell ratio (126), an enhanced expression of HLA class II anti-
gens on biliary epithelial cells (127), and a significantly increased concentration of 
serum intercellular adhesion molecule-I (128). Whether these changes are primary 
or secondary remains to be elucidated. 
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Treatment 
At the end of 1994, PSG was not curable. The effects of a number of therapeutic 
agents and of endoscopic interventions were assessed, which will be discussed 
below. 
UDeA monotherapy 
When, in 1994, the beneficial effects of UDGA on serum liver function tests in PBG 
were established, this drug was also evaluated in PSG (129-135). Results were 
identical: Significant improvements in serum liver function tests were observed 
without significant changes in symptoms. UDGA became the predominant bile salt 
in serum and in bile. In one study, improvements in histological findings were 
observed (132). The effects of UDGA on survival were unknown at the end of 
1994. 
Other medical treatment 
Until the end of 1994, less than 5 randomised clinical trials have been performed in 
PSG. The effects of d-penicillamine have been evaluated in a 3-year randomised 
controlled trial in 70 PSG patients. The absence of any effects of the drug on liver 
function tests, histology, cholangiographic findings and histology in combination 
with serious adverse events in 21 % of patients taking the drug, made the authors 
conclude that additional trials with d-penicillamine should be discouraged (136). 
Several immunosuppressive drugs have been evaluated. After they had shown the 
beneficial effects of methotrexate in PSG in 2 series of case studies (137, 138), 
Kaplan et al reported the results of a 2-year randomised controlled trial assessing 
the effects of methotrexate in 24 PSG patients. No changes in serum liver tests, 
histology, cholangiographic findings and histology were found and the authors con-
clude that the use of methotrexate in PSG must not be recommended (137). 
Although beneficial effects of colchicine in a single patient have been reported 
(139), results of a 3-year randomised controlled trial in 84 PSG patients did not 
show any effects of 1 mg colchicine per day (140). In 12 patients treated with a 
combination of prednisone and colchicine, there was only a trend towards impro-
ved survival after 2 years of treatment without concomitant improvements in liver 
function tests and histology (141). 
Two series of case studies showed sustained clinical, biochemical and histological 
improvement in PSG patients treated with prednisone mono-therapy (142, 143). 
The use of azathioprine mono-therapy has been reported in 2 case reports; one 
patient showed marked improvements (144), whereas the other patient died of 
complications (145). 
No effects of cyclosporine on serum liver function tests or survival have been 
observed in a randomised controlled trial of 2 years in 34 patients (146). 
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Endoscopic intervention therapy 
The strictures of the bile ducts, which causes back pressure and debris formation, 
are accessible for decompression during ERG. Endoscopic procedures could be 
an effective therapeutic strategy for extra-hepatic dominant strictures, because 
these procedures can be performed with relative ease and be repeated with limited 
discomfort and risk to the patient (147). Several case series are described applying 
different techniques to manage symptomatic disease, including endoscopic dilata-
tion with bougies or balloons, removal of debris, stenting and biliary lavage. 
Results are identical: marked and sustained improvements are achieved in serum 
liver function tests, especially an improvement in bilirubin, and in clinical symptoms 
without serious risks to the patient (147-152). After an initial report describing 
favourable effects of biliary lavage with a combination of normal saline and predni-
solone through a naso-biliary drain (153), this procedure has been evaluated in a 
randomised trial. In this study, comparing the effects of biliary lavage with normal 
saline versus lavage with a solution of prednisolone, biochemical values remained 
unchanged or worsened in all patients, while bacterial colonisation occurred in all 
patients within a few days after start of the lavage. No cholangiographic changes 
were seen. The authors conclude that biliary lavage is not beneficial in PSG (154). 
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1.3 Aims of this thesis 
In PBC: 
1. To evaluate the course of serum liver function tests during treatment with UDCA 
for a period of more than 4 years and to assess which factors predict survival in 
our patient cohort, in particular the prognostic value of biochemical remission 
and bilirubin during UDCA therapy. 
2. To investigate whether treatment with a dose of 20 mg UDCA /kg/day is superi-
or to a dose of 10 mg UDCA /kg/day regarding symptoms, liver biochemical 
values, biliary enrichment with UDCA and to describe possible side-effects of 
treatment with high dose UDCA. 
3. To evaluate, in a randomised controlled design, the possible beneficial effects of 
azathioprine and prednisone added to UDCA on symptoms, histology and bio-
chemical markers of cholestasis, inflammation and fibrogenesis. 
In PSC: 
4. To study in a cohort of patients treated with UDCA: its effects on symptoms, his-
tology, cholangiographical findings and serum liver function tests. To study 
whether a multiple daily dose scheme of UDCA is superior to a single dose 
scheme and to compare predicted survival with the observed survival after 2 
years of treatment. 
5. To assess the effects of treatment with a combination of UDCA and a corticos-
teroid (budesonide or prednisone) on symptoms, liver biochemistry and to com-
pare the anti-proliferative properties in bile before and after this treatment in a 
lymphocyte stimulation test. 
6. To study the overlap syndrome of PSC and AIH. 
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ten Kate3, Gerard P van Berge-Henegouwen4, Solko W Schalm 1 for the Dutch 
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1 Dept. of Hepatogastroenterology, University Hospital Rotterdam; 2Dept. of Biosta-
tistics, Erasmus University Rotterdam; 3Dept. of Pathology, Academic Medical 
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Summary 
Background: Serum bilirubin is a prognostic factor in untreated primary biliary cir-
rhosis (PSC), but this has been less extensively documented for patients treated 
with ursodeoxycholic acid (UDCA). Aims of this study were to define the effects of 
UDCA on serum liver tests and to assess prognostic factors in patients on pro-
longed UDCA treatment. 
Methods: Analysis of laboratory parameters obtained before and during treatment 
with UDCA of 203 PSC patients who were followed for a mean of 48 months. Uni-
variate and multivariate analyses were performed to assess the prognostic value of 
pre-entry and follow-up variables with respect to treatment failure and survival. 
Results: Actuarial 5-year incidence of treatment failure and transplantation-free 
survival were 27% and 79%, respectively. According to the univariate analysis the 
following variables were significantly associated with prognosis: pre-entry presence 
of cirrhosis and pre-treatment levels of serum bilirubin and albumin, bilirubin levels 
during follow-up, the occurrence of biochemical remission and normalisation of 
serum bilirubin. Multivariate analysis revealed that bilirubin during follow-up proved 
to be the best predictor. Alkaline phosphatase (APh), aspartate aminotransamina-
se (AST) and immunoglobulin M (lgM) decreased significantly during the first 6 
months of treatment and subsequently remained at this lower level. Serum bilirubin 
showed the same initial pattern but a significant increase was observed after 4 
years of treatment. 
Conclusions: Serum bilirubin in both UDCA-treated and untreated patients is the 
most powerful predictor of prognosis for PSC. The partial therapeutic efficacy of 
UDCA is illustrated by the finding that serum bilirubin, in contrast to APh and the 
transaminases, appears to increase after 4 years of treatment. 
30 
Introduction 
Ursodeoxycholic acid (UDCA) has been established as the treatment of choice for 
primary biliary cirrhosis (PSC) since it is safe, virtually free of adverse effects and 
prolongs (transplantation-free) survival (1-5). Within 3 months of treatment with 
UDCA, pronounced beneficial effects are observed for liver biochemical parame-
ters, especially liver tests indicative of cholestasis and inflammation, and serum 
immunoglobulin M (lgM), which is characteristically elevated in PSC (3, 5-10). The 
effects of UDCA on biochemical parameters beyond 2-3 years have not been well 
documented. In the reports of 4 major placebo-controlled trials to assess the 
effects of UDCA in PSC (1-4), these data were provided for a maximum follow-up 
period of 3 years. Leuschner et al. reported sustained improvement in glutamate 
dehydrogenase, alanine aminotransaminase (ALT) , alkaline phosphatase (APh) 
and IgM in 22 patients who were followed for 4 to 12 years (11). 
PSC has many features indicative of an autoimmune-mediated pathogenesis (12-
14). As in other autoimmune diseases, e.g. autoimmune hepatitis, biochemical 
remission of the disease could be indicative of a subsequently favourable long-
term outcome. For PSC, the significance of biochemical remission has not been 
determined. 
The importance of bilirubin as a prognostic factor has been established in un-
treated PSC patients (15-18). In UDCA-treated PSC patients, serum bilirubin has 
been reported to remain a useful prognostic marker (19). 
The present study was conducted to evaluate prognostic factors, including the 
occurrence of biochemical remission, and to define the long-term effects of UDCA 
on biochemical parameters in a cohort of patients with compensated PSC. 
Patients and methods 
A prospective follow-up study of a cohort of PSC patients, who were treated with 
UDCA according to a pre-defined protocol, was performed. The diagnosis of PSC 
was established on the basis of previously published criteria (20). Liver biopsy at 
entry was optional; however, a requirement at entry was that a biopsy specimen 
had to be available for histological review that showed features compatible with the 
diagnosis of PSC. The study was started in May, 1990, and follow-up data until 29 
February, 1996, were used for the analyses. Patients were recruited and followed 
in 44 centres in The Netherlands. Exclusion criteria were age> 75 years, (risk of) 
pregnancy, evidence of extra-hepatic bile duct disease, treatment with UDCA in the 
3 months before entry, concomitant serious disease limiting life expectancy and 
decompensated PSC, defined as cirrhosis with Child-Pugh class S or C disease. 
UDCA (Ursochol®, Zambon Nederland SV, Amersfoort, The Netherlands) was 
administered in a single dose of 10 mg per kg bodyweight per day at bedtime. Fol-
low-up data were collected at 3-months intervals during the first year and every 
half year thereafter. At each visit a general clinical examination and blood studies 
including serum total bilirubin, APh, aspartate aminotransaminase (AST) , albumin 
and 19M, were performed. Liver biopsy specimens were reviewed by the trial 
pathologist (FJWtK) and staged according to Ludwig et al. (21). 
31 
Statistical analysis 
Laboratory parameters were expressed as multiples of the upper limit of normal 
(ULN), except for albumin which was expressed as multiples of the lower limit of 
normal (LLN). The course of laboratory parameters was analysed using a repeated 
measurement model (SAS for windows® version 6.11: proc mixed) after logarith-
mic transformation. Treatment failure was defined as death, liver transplantation, 
twofold increase in serum bilirubin, variceal bleeding or de novo ascites. Biochemi-
cal remission was defined as the simultaneous normalisation of serum bilirubin 
and AST with APh :;;1.5 x ULN. Transplantation-free survival, time to treatment fai-
lure and time to biochemical remission were computed by the Kaplan-Meier 
method and compared between groups by means of the log-rank test. Multivariate 
Cox analyses with backward elimination procedures were used to examine 
prognostic factors at entry and during follow-up (with time-dependent factors). 
Analysis of the predictive value of cirrhosis versus non-cirrhosis was performed for 
patients who had undergone liver biopsy within the year before entry or who had 
had cirrhosis in a previous biopsy. A p-value :;;0.05 was considered statistically 
significant. 
Results 
The study population consisted of 203 patients; 179 (88%) were female. Five 
patients tested negative for anti mitochondrial antibodies. In all cases histology was 
compatible with the diagnosis of PBC. A liver biopsy had been obtained in 99 
patients within the year before entry; for 16 of the remaining 104 patients cirrhosis 
had already been documented histologically (table 1). 
Median follow-up was 47.3 (10-90 percentile: 10-60) months. Twelve patients 
(5.9%) who were lost to follow-up, were censored at the moment of their last visit. 
UDCA was discontinued in 5 cases because of gastro-intestinal complaints (n=3), 
deteriorating biochemical values (n=1) and the patient's wish to stop therapy (n=1). 
Treatment failure/death 
The group treatment failure consisted of 34 patients (table 2). Fourteen patients 
died: 2 from decompensation of the disease, 2 from hepatocellular carcinoma, 1 
from hepatorenal syndrome, 1 from variceal bleeding and 8 from non-hepatological 
causes. 
Five-year transplantation-free survival was 79% and treatment failure occurred in 
27% of cases (figure 1). Patients with cirrhosis at entry had a significantly de-
creased five year transplantation-free survival (65% vs. 94%; fJ<0.01) and ex-
perienced more treatment failure (72% vs. 21 %; fJ<0.01) compared to non-cirrhotic 
patients. No differences in the incidence of treatment failure or death were obser-
ved among Ludwig's histological stages I, II and III. In an univariate model, biliru-
bin, albumin, AST, normalisation of bilirubin, biochemical remission and bilirubin 
during follow-up were found to be of predictive significance for both treatment 
failure and death (table 3). 
Three multivariate models were used (tables 4 and 5). All models included the 
variables given in table 3, but biochemical remission (model A), normalisation of 
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bilirubin (model B) and biliru-
bin during follow-up (model C) 
were included separately to 
avoid an excess of parame-
ters. From the backward elimi-
nation procedure it appeared 
that bilirubin at entry or during 
follow-up was the most signifi-
cant prognostic factor. In all 
models, age was also a pre-
dictor of death and transplan-
tation, while the presence of 
cirrhosis predicted treatment 
failure. 
Biochemistry 
Within the first 6 months 
of follow-up, serum bilirubin 
(-6.5%; standard deviation 
(sd) 2.3; p<0.01 )(figure 2), 
APh (-38.7%; sd 1.6; p<0.01), 
AST (-39.9%; sd 1.9; p<0.01), 
IgM (-18.9%; sd 2.8; p<0.01) 
and albumin (+2.2%; sd 0.9; 
p=0.02) (figure 3) gradually 
improved. APh, AST and IgM 
remained stable during further 
follow-up. Bilirubin, however, 
started to rise after 4 years 
(p<0.05). 
Biochemical remission 
The actuarial percentage of 
patients who exhibited bioche-
mical remission at any time 
during follow-up was 42% 
(95% confidence interval (95 
CI) 35%-49%) at 1 year and 
54% (95 CI 46%-62%) at 5 
years. In 50% of patients bio-
chemical remission was main-
tained for 21 months (95 CI 
11 %-31 %); the actuarial per-
centage of patients in sustai-
ned remission after 5 years 
Table 1: Patient characteristics at entry. 
Total group 
n~203 
Age (years; meanS D) 56.3 (±1 0.7) 
Sex (male/female) M 24/ F 179 
Alkaline phosphatase (ULN) 3.0 (1.2-8.3) 
AST (ULN) 1.7 (0.8-3.8) 
Bilirubin (ULN) 0.8 (0.3-2.9) 
- patients (no) with 
bilirubin> 1 X ULN 37 (19%) 
bilirubin> 2 x ULN 20 (10%) 
Albumin (LLN) 1.1 (0.8-1.3) 
IgM (ULN) 2.0 (0.7-6.7) 
Histological stage 
I 16 
II 40 
III 30 
IV 29 
Biochemical data are shown as geometric 
means with percentiles (5%; 95%) in 
parentheses. Histological stage provided 
for patients with previously established cir-
rhosis or sampled within the year before 
entry. 
Table 2: Reason for first treatment failure. 
Event n 
Death 13(14) 
Transplantation 4 (10) 
Doubling bilirubin 12 
Variceal bleeding 1 
De novo ascites 4 
Total number of events in parentheses 
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Table 3: Univariate analysis of possible predictors of prognosis. 
Death - transplantation Treatment failure 
Covariate p RR 95%CI P RR 95%CI 
Age 0.03 1.03 0.99-1.08 0.01 1.01 0.97-1.04 
Cirrhosis 2.1 8.3 2.2-32.0" 1.9 6.6 2.5-17.9" 
Bilirubin at entry 2.8 17.0 4.9-59.1" 2.5 12.5 4.3-36.6" 
AST at entry 1.7 5.7 0.9-34.6 1.5 4.5 1.0-21.0' 
APh at entry 0.4 1.4 0.3-7.0 1.1 2.9 0.7-11.4 
IgM at entry -0.6 0.5 0.1-2.9 -0.3 0.8 0.2-2.9 
Albumin at entry -3.5 0.03 0.002-0.4" -3.5 0.03 0.002-0.3" 
Biochemical remission -1.4 0.3 0.1-1.1 -1.8 0.2 0.04-0.7' 
Normalisation bilirubin -2.0 0.1 0.1-0.3** -1.8 0.2 0.1-0.4" 
Bilirubin during follow-up 3.1 21.0 7.7-57.7" 2.7 14.9 6.2-35.r 
'ps;0.05; .. ps;0.01 
Table 4: Multi-variate analysis of possible predictors of death or transplantation. 
Death - transplantation 
Covariate p RR (95% CI) 
Final model A Age 0.05 1.1 (1.0-1.1)' 
Bilirubin at entry 3.2 25.3 (6.6-97.7)" 
Final model B Age 0.05 1.1 (1-1.1)' 
Bilirubin at entry 3.2 25.3 (6.6-97.7)" 
Final model C Age om 1.1 (1.0-1.1)' 
Bilirubin during follow-up 3.6 36.3 (11.9-110.5)" 
'ps;0.05; "ps;0.005 
Full model included all variables listed in table 3. 
was 34% (95 CI 21%-47%). Univariate analysis showed that low age, absence of 
cirrhosis and low values of AST, ALT, APh, bilirubin and IgG at entry significantly 
predicted biochemical remission. Low AST (relative risk (RR)=0.14; 95 CI 0.05-0.5; 
11=0.002), APh (RR=0.08; 95 CI 0.03-0.23; p<0.0001) and bilirubin (RR=0.21; 95 CI 
0.08-0.55; 11=0.001) were all predictive of biochemical remission in a multivariate 
model. 
34 
Table 5: Multi-variate analysis of possible predictors of treatment failure. 
Treatment failure 
Covariate ~ RR (95% CI) 
Final model A Cirrhosis 1.1 2.9 (1.0-9.1)" 
Bilirubin at entry 2.3 1 0.1 (2.8-6.2)'" 
Final model B Cirrhosis 1.3 3.7 (1.3-10.6)" 
Normalisation bilirubin -1.6 0.2 (0.1-0.5)'" 
Final model C Cirrhosis 1.1 3.0 (1.0-8.5)' 
Bilirubin during follow-up 2.6 13.0 (4.9-33.8)'" 
'p50.1; "p50.05; '" p5 0.005 
Full model included all variables listed in table 3 
Discussion 
In the past, serum bilirubin has been demonstrated to be one of the most impor-
tant prognostic factors in PSC. This study not only confirms that treatment with 
UDCA decreases serum levels of bilirubin but also shows that pre-treatment biliru-
bin levels remain of significant prognostic value for patients treated with this agent. 
Most importantly, our results indicate that during the treatment serum bilirubin also 
provides the most powerful prognostic information. This implies that in clinical prac-
tice serum bilirubin values do not have to be "corrected" for the fact that a patient is 
receiving UDCA. We confirm previous observations that for UDCA-treated patients 
serum bilirubin (4, 19) and normalisation of serum bilirubin during therapy (22) are 
of important prognostic significance. 
The definition of biochemical remission used in this study was a modification of the 
definition proposed for autoimmune hepatitis (23, 24). Consistent with another 
recent study (25), the achievement of biochemical remission was significantly 
associated with a better prognosis, suggesting that biochemical remission might 
be an important short-term therapeutic goal in PSC. In the mUltivariate analysis, 
however, the prognostic significance of biochemical remission was not apparent. 
Combined analysis of the French (3), Mayo Clinic (1) and Canadian (6) randomi-
sed controlled trials to evaluate the effects of UDCA in PSC showed a significantly 
longer survival free of transplantation in UDCA-treated patients (4). In these stu-
dies the 4-year transplantation-free survival rate was approximately 80%, which is 
comparable with the 88% 4-year survival rate observed in the present study. The 
slightly beller value may be explained by variations in patient selection since our 
patients had less advanced disease. 
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This study further suggests that the effect of UDCA therapy on serum bilirubin is 
temporary, in contrast to the effects on serum transaminases and APh, which were 
maintained for a period of at least 5 years. This observation illustrates that UDCA 
has a limited potential to cure the disease and that long-term treatment does not 
prevent the ultimate development of progressive cholestasis and liver failure. 
When this study was initiated in 1990 a UDCA dose of 10 mg/kg/day was conside-
red adequate and was normal in our country. Two recent studies clearly indicate 
that higher doses have more pronounced effects, especially on APh and transami-
nases (26, 27) and in retrospect the dose we used was not optimal. However, the 
quantitative differences in biochemical response between doses of 10 and 20 
mg/kg/day were rather small (26). In particular, no significant difference in serum 
bilirubin was found for patients treated with 10 mg/kg/day compared with patients 
treated with 20 mg/kg/day (26). It seems therefore unlikely that the main results of 
this study have been influenced in a major way by use of the 10 mg/kg/day dose. 
However, the possibility that higher UDCA doses would have yielded other results, 
especially for the biochemical parameters, must be considered. It seems unlikely 
that our choice for a single-dose regimen has influenced the results of the present 
study, since single- and multiple-dose regimens lead to similar improvements in 
serum liver function test and UDCA enrichment in bile in patients with cholestatic 
liver diseases (28, 29). 
In conclusion, serum bilirubin, in particular during treatment with UDCA, is the fac-
tor that provides the most powerful prognostic information in PSC. The beneficial 
effects of UDCA on laboratory liver tests were sustained for at least 4 years; then 
serum bilirubin levels tended to rise. The latter observation can be considered 
another illustration of the partial therapeutic efficacy of UDCA in PSC, as shown in 
the present and other studies. 
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Figure 1: Proportion of patients who survived without transplantation and without treatment 
failure for the complete cohort or according to histological stage. 
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Figure 3: Geometric means (upper limit of normal) of alkaline phosphatase, aspartate mino-
transaminase (AST), immunoglobulin M (lgM) and albumin during 5 years of treat-
ment with UDCA. Error bars indicate standard error of the mean. 
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CHAPTER 3 
A RANDOMISED CONTROLLED TRIAL 
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Summary 
Background: Ursodeoxycholic acid (UDCA) prolongs transplantation-free survival 
in primary biliary cirrhosis (PBC). However, the optimal therapeutic dose has not 
been established. 
Aim: To compare the effects of UDCA administered in daily doses of 10 versus 20 
mg/kg on symptoms, liver biochemistry and biliary UDCA enrichment. 
Methods: A 6-months multi-centre randomised open controlled trial was conducted 
to assess the effects of an increase in the dose of UDCA to 20 mg/kg/day versus 
continuation of 10 mg/kg/day for patients who had not achieved biochemical nor-
malisation during treatment for at least 6 months with the 10 mg/kg dose. Clinical 
and laboratory evaluations were performed at entry and at 3-months intervals. The 
percentage UDCA in duodenal bile was assessed at entry and at 6 months. 
Results: Sixty-one patients were enrolled. No side-effects of UDCA were observed. 
Within the 20 mg/kg/day group significant decreases were found for alkaline 
phosphatase (-8%; jJ=0.003), aspartate aminotransaminase (-11%; jJ=0.01), alani-
ne aminotransaminase (-17%; p<0.001), y-glutamyl transferase (-34%; p<0.001), 
immunoglobulin M (-11%; jJ=0.002) and cholesterol (-8.1%; p<0.001). In the 10 
mg/kg group none of these parameters differed significantly from baseline. No sig-
nificant differences between the dose groups for symptom scores or serum biliru-
bin were found. Biliary enrichment with UDCA increased from 37% to 46% in the 
20 mg/kg group (jJ=0.02) while remaining stable in the 10 mg/kg group. 
Conclusions: Liver biochemistry improved in PBC patients receiving UDCA 20 
mg/kg/day compared to a dose of 10 mg/kg/day. Both doses were equally well tole-
rated. These results indicate that UDCA 10 mg/kg/day is a suboptimal dose for 
treating PBC. 
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Introduction 
Primary biliary cirrhosis (PBG) is a chronic cholestatic liver disease of unknown 
aetiology, characterised by immune-mediated destruction of intrahepatic bile ducts 
(1-3). The beneficial effects of ursodeoxycholic acid (UDCA) on biochemical para-
meters and transplantation-free survival have been well documented (4-8). How-
ever, surprisingly few data on the optimum therapeutic UDCA dose are available 
(9). In several large controlled trials UDCA was administered in a dose of 13-15 
mg/kglday (4-6), which was based on preliminary findings that this dose was well 
tolerated and resulted in marked biochemical improvements (10). Others, however, 
have used lower doses, varying from 7.7 (II, 12) to 10 mg/kg/day (7, 13, 14). 
The Dutch Multi-centre PBC Study Group chose a dose of 10 mg/kg/day. When 
evaluation revealed that biochemical remission was achieved in 11 % of patients 
and combined clinical, biochemical and histological remission occurred in less than 
5%, the question arose as to whether the UDCA dose was too low (15). 
In view of the paucity of data on the optimum UDCA dose for treatment of PBC, the 
aim of this study was to assess the dose-response relationship and patient toleran-
ce of relatively low (10 mg/kg) versus relatively high (20 mg/kg) doses of UDCA. 
Methods 
Patients with an established diagnosis of PBC (16) from 20 centres in the Nether-
lands were included in this randomised open controlled trial. All patients had com-
pensated disease, defined as the absence of criteria for Child-Pugh class B disea-
se (17), and had been treated with 10 mg UDCA /kg/day for at least 6 months, 
without achieving normalisation of serum bilirubin, alkaline phosphatase (APh), 
aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), y-glutamyl 
transferase (y-GT) or immunoglobulin M (lgM). Patients were randomly allocated 
either to a group which continued to take UDCA 10 mg/kg/day or to a group which 
received 20 mg/kg/day for a period of 6 months. UDCA (Ursochol®; Zambon BV; 
Amersfoort, The Netherlands) was given in two divided daily doses. Follow-up data 
were collected every 3 months. Symptoms, i.e. fatigue and pruritus, were quantified 
using visual analogue scales (VAS). Patients were asked to indicate the severity of 
pruritus and fatigue on a horizontal line for the first 5 days following each visit. 
Blood analyses included: bilirubin, AST, ALT, APh, y-GT, immunoglobulin G (lgG), 
IgM, cholesterol and haematological indices. Biochemical remission was defined 
as normal val ues for bilirubin, AST and IgM and APh $ 1.5 upper limit of normal 
(ULN). All patients gave informed consent; approval was obtained from the medical 
ethics committees of the participating centres. 
Bile acid analysis 
Duodenal bile was collected at entry and at 6 months using the Enterotest® 
method (18, 19). Patients came to the hospital in the fasting state and swallowed 
the Enterotest® string with water, the oral end of the string being taped to the cor-
ner of the mouth. The string was removed after 4 hours and stored at -20°C until 
further analysis. 
Bile acids were eluted from the distal, absorbent part of the string, usually the last 
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10--15 cm, by three consecutive washes with 5 ml 0.5 M phosphate buffer, pH 7.0, 
in an ultrasound bath (18). Bile salts were extracted from the buffer by means of 
solid-phase extraction using Sep-Pak C18 cartridges (Waters Inc., Milford, MA, 
USA). Bile acids were eluted from the cartridge with 3 ml of methanol. Total bile 
salt concentration was analysed enzymatically in the phosphate buffer and in the 
methanolic extract from the string (20). It appeared that 85% of the total bile salt 
pool was recovered in the phosphate buffer and additional washes of the string 
with methanol increased the total recovery to a limited extent only. Therefore, the 
buffer extract was used for further analysis. 
Bile salt species were analysed by capillary gas-liquid chromatography on a CP Sil 
19 CB fused silica column (Chrompack BV, Middelburg, The Netherlands). Bile 
acids were enzymatically hydrolysed (choloylglycine hydrolase; Sigma Chemical 
Co., St. Louis, MO, USA) and converted to methylester-trimethylsilyl derivatives 
using acetylchloride/methanol (Merck, Darmstadt, Germany) and hexamethyldisila-
zane/trimethylchlorosilane (Pierce, Rockford, II, USA) (21, 22). Chromatograms 
were analysed with Shimadzu Scientific Instrument Inc. Class-VP software. 
Statistical analysis 
Data were analysed on an intention-to-treat basis. To detect differences of at least 
75% of the standard deviation in the main laboratory parameters between the 
treatment groups, with a significance of 0.05 and a power of 80%, it was calculated 
that a sample size of 60 patients was needed. After stratification for the presence 
of cirrhosis, randomisation was performed centrally at the University Hospital Rot-
terdam. Laboratory parameters were expressed as multiples of the ULN. Data at 3 
months were compared with baseline using the signed-rank test. The change from 
baseline of logarithmically transformed laboratory parameters was analysed using 
repeated measurements analysis of variance (rmANOVA). Symptom scores and 
biliary enrichment with UDCA were compared by means of Student's t-test. Factors 
determining biochemical values at 6 months were assessed by multiple regression 
analysis. A p-value equal to or less than 0.05 was considered significant. 
Results 
Of the 61 patients studied, 28 were allocated to the group continuing with UDCA 
10 mg/kg/day (actual mean dose 9.8 mg/kg, standard error of the mean (SEM) 0.5) 
and 33 to the 20 mg/kg/day dose group (actual mean dose 20.3 mg/kg, SEM 0.7). 
Patients were well matched for baseline characteristics (table 1). During follow-up, 
1 patient in the 10 mg group developed progressive liver failure within 1 month and 
was withdrawn from the study. One patient (20 mg/kg group) was lost to follow-up 
immediately after entry. 
One patient in the 20 mg/kg group complained of diarrhoea during the first 2 
weeks of the study. Clinical evidence suggested that this was due to intercurrent 
viral gastro-enteritis. No other adverse events were noted. No adverse effects on 
haematological indices or renal function (serum creatinine) were found. 
AnalysiS of scores for fatigue and pruritus, which were comparable at entry, re-
vealed no changes within or between groups. 
44 
Table 1: Features at entry. 
UDCA UDCA 
10 mg/kg/day 20 mg/kg/day 
Variable n=28 n=33 
Mean age (range) 55 (37-76) 59 (34-73) 
Sex (male/female) M 3/ F 25 M 3/ F 30 
Pruritus (n) 8 9 
Fatigue (n) 17 20 
Cirrhosis (n) 6 6 
Bilirubin 0.9(0.11) 0.9 (0.18) 
Albumin 0.9 (0.02) 0.9 (0.01) 
APh 1.7 (0.2) 1.9 (0.2) 
y-GT 3.5 (0.77) 3.8 (0.62) 
AST 1 (0.07) 1.1 (0.16) 
ALT 1.1 (0.11) 1.4 (0.27) 
IgG 1 (0.06) 0.87 (0.04) 
IgM 1.95 (0.29) 1.7 (0.23) 
Cholesterol 0.9 (0.04) 1.0 (0.05) 
Biochemical values are expressed in means of ULN with standard error in 
parentheses. 
At 3 months, in the 20 mg/kg group, APh (-8%; p=0.003), y-GT (-34%; p<O.001), 
AST (-11%; p=0.01), ALT (-17%; p<0.001), IgM (-11%; p=0.002) and cholesterol 
(-8.1 %; p<0.001) (figure 1) were all significantly decreased compared to baseline 
values. In the 10 mg/kg group, liver function tests did not change significantly. 
Compared with the 10 mg/kg group, the decrease at 3 and 6 months was signifi-
cantly larger for APh (p =0.006), y-GT (p<0.001), AST (p<0.001), ALT (p<0.001), 
IgM (p=0.01) and cholesterol (p<0.001) in the 20 mg/kg group (rmANOVA). Biliru-
bin and IgG remained the same in both groups. At 6 months biochemical remission 
was observed in 1 (4%) and 4 (12%) patients in the 10 and 20 mg/kg dose groups, 
respectively (not significant (ns)). 
Duodenal bile was collected from 57 patients at entry; 3 patients (one from the 1 0 
mg/kg group) refused to undergo the procedure and the test failed in 1 case (10 
mg/kg dose). After 6 months duodenal bile was collected from 52 patients; 7 
patients refused to undergo the procedure (five from the 20 mg/kg group) and it 
was not performed for other reasons in 2 cases. Bile acid analysis was successful 
for 43/57 (75%) samples obtained at entry and 44/52 (85%) of the 6-month sam-
ples. The main reason for failure was sampling of insufficient bile acid via the 
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Figure 1: Percentage change from baseline values for alkaline phosphatase, y-glutamyl 
transferase, aspartate amino transaminase, alanine amino transaminase, immu-
noglobulin M and cholesterol for the 10 mg/kg and 20 mg/kg UDCA dose groups. 
Error bars indicate standard error of the mean. Values for the 20 mg/kg group are 
significantly lower compared to both the 10 mg/kg group and baseline values. 
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string. At entry biliary enrichment with UDCA was 35% (SEM 4.3%) in the 10 
mg/kg group and 33% (SEM 2.9%) in the 20 mg/kg group (p=ns.). After 6 months 
of treatment biliary enrichment remained stable (37%; SEM 3.4) in the 10 mgikg 
group and had significantly increased to 46% (SEM 2.6) in the 20 mg/kg group 
(p=0.02) (figure 2). No significant correlations were found between the changes in 
any of the laboratory parameters and the change in UDCA enrichment. From fur-
ther analysis by a multiple regression model, which included dose group, biochemi-
cal value at entry and biliary enrichment at 6 months, it appeared that biochemical 
values at 6 months were primarily associated with the dose group and not with 
biliary enrichment. The same applied to the increase in biliary enrichment. When 
UDCA enrichment at entry for patients with and without cirrhosis was compared, 
no significant differences were found either for the total group of patients or for the 
2 dose groups separately. At 6 months, UDCA enrichment in the 20 mg/kg group 
was 36% for those with established cirrhosis and 49% for those without cirrhosis, 
respectively (p<0.05). 
Discussion 
Our data indicate that for patients with PBC, treatment with UDCA in a dose of 20 
mg/kg/day results in greater UDCA enrichment of bile and greater improvements in 
liver biochemistry than treatment with 10 mg/kg/day. Both doses were equally well 
tolerated, confirming previous experience obtained with UDCA 20 mg/kg/day in 
other cholestatic disorders (23-25). The further improvements obtained with the 
higher UDCA dose were, however, not associated with a favourable effect on 
symptoms. 
For patients treated with UDCA, biliary enrichment is determined by the intestinal 
absorption of UDCA and the subsequent uptake and excretion by the liver. Pre-
vious studies of patients with (9, 24-27) and without liver disease (28, 29) have 
shown that higher doses of UDCA lead to greater biliary enrichment, although the 
relative intestinal absorption of UDCA may decrease simultaneously (27, 30). Bilia-
ry enrichment with UDCA was found to be related to biochemical improvement in 
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some (9, 31, 32) but not all studies (7, 26). The factors, which ultimately determine 
the degree of biliary UDCA enrichment that can be obtained in individual patients, 
have not been clearly defined. It remains to be established whether doses higher 
than those used in this study will further enhance biliary enrichment with UDCA. 
Although the number of cases was limited, our results suggest that the maximum 
biliary enrichment that can be obtained is lower for patients with cirrhosis than for 
non-cirrhotics. In advanced stages of PBC, decreased bile production may impair 
intestinal UDCA absorption. Biliary UDCA enrichment is also determined by the 
capacity of the liver to excrete UDCA into bile and decreasing enrichment was 
found to be associated with increasing cholestasis and the presence of cirrhosis 
(33). Studies of cystic fibrosis have shown that in this disease biliary enrichment is 
relatively low, due to malabsorption of the bile acids; a 20 mg/kg/day dose has 
been found to increase biliary UDCA enrichment and the biochemical response 
compared to a 10 mg/kg/day dose (24, 25). 
Our results appear to confirm previous reports (6, 34) that UDCA treatment has no 
clear effect on symptoms. However, our patients had already been treated for at 
least 6 months and symptomatic benefit may have occurred earlier. In this context 
it should also be noted that the further biochemical improvements observed with 
the higher UDCA dose were quantitatively rather small. 
In view of the results of this study one might question whether PBC patients should 
be treated with a UDCA dose of at least 20/mg/kg. Theoretically, it seems logical to 
use a dose, which has been found to exert the most pronounced effects. To assess 
whether this dose is therapeutically more potent in preventing end-points such as 
death or liver transplantation would require a randomised controlled trial with a 
long period of follow-up. Moreover, given the already established efficacy of UDCA 
treatment and the small differences in the effects of 'low' and 'high' doses, many 
hundreds of patients would be needed. Therefore, studies to actually prove the 
superiority of one dose regimen over the other hardly seem feasible. 
Recently, a study similar to ours (35) was published in abstract form, where UDCA 
in doses of 5-7,13-15 and 22-25 mg/kg/day were compared. No differences were 
found between the 13-15 and 22-25 mg/kg groups while both doses resulted in a 
significantly greater biochemical improvement than the lower dose. Based on these 
and our own findings, the conclusion that UDCA at a dose of 13-15 mg/kg/day is 
the most (cost)-effective dose for treating patients with PBC seems justified. 
Our method for collection of duodenal bile by means of the Enterotest® has pre-
viously been validated (18, 36). Duodenal bile has been reported to be qualitatively 
similar to gall-bladder bile (37, 38). The Enterotest method does not require duo-
denal intubation and therefore may be more easily tolerated and accepted by 
patients. In several cases we were unable to perform bile acid analysis due to 
insufficient recovery of bile, a problem also reported by others (39). Therefore, to 
increase the diagnostic yield when using this method, one might consider stimula-
ting gall-bladder contraction (39). The 37% biliary UDCA enrichment found at 
baseline is comparable with the findings of others, who reported a 31-40% enrich-
ment with UDCA in bile collected by duodenal intubation from patients treated with 
UDCA doses ranging from 8 to 15 mg/kg/day (7, 34, 40, 41). 
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The exact mechanism of action of UDCA in PBC is still subject to debate. UDCA 
decreases the hydrophobicity index of the bile acid pool and may prevent liver cell 
damage caused by endogenous hydrophobic bile acids (42-44). Furthermore, sta-
bilisation of cell membranes (45, 46) and a choleretic effect may contribute to the 
therapeutic effect of UDCA (47). Although the therapeutic effect of UDCA in chole-
static liver disease may correlate with the degree of UDCA enrichment of the bile 
acid pool, this could not be confirmed in our study, suggesting the importance of 
other factors in the mechanism of action of UDCA. 
In conclusion, for patients with PBC, treatment with UDCA at a dose of 20 
mg/kg/day, which is well tolerated, results in greater biliary enrichment with UDCA 
and has a more pronounced effect on biochemical liver function tests than a 10 
mg/kg/day dose. Consequently, the latter dose is not optimal. Given the results of 
the recently reported trial by Lindor et aI., UDCA at a daily dose of 13-15 mg/kg 
appears to be the preferred dose. 
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Summary 
Background: Treatment with ursodeoxycholic acid (UDCA) has been shown to 
decrease the rate of disease progression in patients with primary biliary cirrhosis 
(PBC), although the effect is modest. Since PBC has many features of an autoim-
mune disorder, immunosuppressives added to UDCA may be of value in the treat-
ment of PBC. 
Methods: A 1 year randomised, double-blind, placebo-controlled trial was carried 
out in 50 patients with PBC, who had already been treated with UDCA for at least 
1 year, but had not achieved complete disease remission. Patients were randomi-
sed to additional prednisone (30 mg/day initially, tapered to 10 mg daily after 8 
weeks) and azathioprine (50 mg daily) or placebo. A subgroup of patients received 
cyclical etidronate and calcium. The principal aim of the study was to assess the 
short-term benefits and risks of the combined bile acid and low-dose immunosup-
pressive regimen. Primary endpoints were effects on symptoms, liver biochemistry, 
liver histology, bone mass and the occurrence of adverse events. 
Results: Pruritus (p=0.02), alkaline phosphatase, aspartate aminotransaminase, 
immunoglobulin M and procoliagen-Ill-propeptide improved significantly (all 
p<O.002) in the combined treatment group as compared to the placebo group. His-
tological scores for disease activity and disease stage decreased significantly with-
in the combination treatment group (p<O.001). 
Conclusions: In patients with PBC receiving UDCA, there is an additional benefi-
cial effect of 1-year treatment with prednisone and azathioprine on symptoms and 
biochemical, fibrogenetic and histological parameters. These results strongly 
encourage the evaluation of this triple treatment regimen in long-term controlled 
trials of adequate size to document its effect on clinical events. 
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Introduction 
Currently, ursodeoxycholic acid (UDCA) is the standard treatment for primary bilia-
ry cirrhosis (PBC) (1, 2). However, the potential of UDCA to improve the natural 
course of the disease is modest and complete remissions are achieved in less 
than 5% of patients (3). The combination of UDCA with other drugs has therefore 
been suggested as a logical nex1 step (4, 5). Theoretically, the addition of immuno-
suppressive drugs to UDCA is attractive because UDCA, interfering mainly with 
endogenous bile-acid-mediated liver damage, is unlikely to stop the primary immu-
ne damage occurring in PBC (4, 5). 
Both prednisone (6-8) and azathioprine (9, 10) have been shown to be of some 
benefit in PBC. Prednisone has been considered contraindicated due to its negati-
ve effect on bone status, which was mainly observed in patients with advanced 
PBC and jaundice (11). In compensated patients, however, no major adverse 
effects of low-dose prednisone on bone mass was found (12). Moreover, drugs like 
bisphosphonates may prevent steroid-associated bone loss (13-15). 
Azathioprine has not been accepted as therapy for PBC since the observed small 
benefit in life expectancy did not neutralise the fear for an increased risk of neo-
plasms (10). Long-term follow-up of patients with autoimmune diseases treated 
with prednisone/azathioprine indicates that this fear is unwarranted (16, 17). 
As in autoimmune hepatitis, combining low doses of prednisone and azathioprine 
may lead to an increased immunosuppressive potential without enhancing the risk 
of side effects. Before starting a long-term study, the potential benefits and risks of 
combined UDCA, prednisone and azathioprine treatment versus UDCA monothe-
rapy, were investigated in a 1-year, multi-centre, double-blind, placebo-controlled 
trial in PBC patients who had not completely responded to UDCA alone. 
Patients and methods 
All patients had an established diagnosis of PBC (18). Exclusion criteria were age 
> 75 years, extrahepatic bile duct disease, (risk of) pregnancy, the use of other 
potential disease modifying drugs (e.g. corticosteroids, d-penicillamine, azathiopri-
ne, colchicine) within 6 months before entry, known intolerance for prednisone or 
azathioprine, osteoporotic spinal fractures, systemic infections, a psychiatric histo-
ry or cyt0Benia (defined as white bloodcell count (WBC) < 2.5 x 109/1, platelets 
< 70 x 10 /1 or haemoglobin (Hb) < 6 mmolll). Patients with Child-Pugh classifica-
tion B or C (19) were excluded since they were considered unlikely to benefit from 
medical treatment. 
All patients had been treated with UDCA (ca. 10 mg/kg/day) for at least one year 
and none of them had achieved a complete remission of the disease, according to 
previously formulated criteria (5). After stratification (presence versus absence of 
cirrhosis and centre) patients were allocated at random to additional 
prednisone/azathioprine or placebo for 1 year. Both clinicians and patients were 
unaware of the treatment allocation. 
Prednisone and identical-looking placebo tablets were taken in a dose of 30 mg 
daily for the first month, 20 mg in the second month and 10 mg for the remaining 
10 months. One tablet containing 50 mg azathioprine or placebo (Glaxo Wellcome 
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BV, Zeist, The Netherlands) was taken daily. After one year, prednisone was gradu-
ally withdrawn during four weeks and azathioprine was stopped. 
All patients received calcium carbonate 500 mg daily. In 2 centres in the Rotterdam 
area, patients were randomly assigned to treatment with 3-monthly cycles of eti-
dronate 400 mg daily for 2 weeks (Procter & Gamble Pharmaceuticals BV, Rotter-
dam, The Netherlands) or placebo (20). All other patients received open label eti-
dronate. Patients with subnormal 25-0H vitamin D levels received 600,000 I U cho-
lecalciferol intramuscularly once. Patients visited the outpatient department month-
ly during the first 3 months and at 3-months intervals thereafter. At each visit a 
physical examination, including weight and blood pressure measurements and 
laboratory investigations (Hb, WBC, platelets, serum bilirubin, alkaline phosphata-
se (APh), aspartate aminotransaminase (AST) , albumin and immunoglobulin M 
(lgM)) were performed. For the 5 days following each visit, patients were asked to 
grade itching and fatigue on a scale from 0 (absent) to 4 (severe) for the morning, 
afternoon, evening and night, resulting in a total score ranging from 0-16 per day. 
Analysis was based on the total score of 5 consecutive days (minimal score 0; 
maximal score 80). 
In the two Rotterdam centres (24 patients), fasting serum aliquots were taken be-
fore start of the immuno-suppressive treatment and at 3, 6 and 12 months for 
radioimmunoassay of procollagen-III aminoterminal propeptide concentrations 
(P-III-P), using a commercially available kit (Orion Diagnostica, Espoo, Finland). 
Prior to the study and after 1 year, liver biopsies and Dual Energy X-ray Absorptio-
metry (DXA) measurements of Bone Mineral Density (BMD, in grams hydroxyapati-
te/cm2 ) of the lumbar spine (L2-L4) and femur neck were performed. The biopsies 
were reviewed by one pathologist (FJWtK), who was unaware of the treatment allo-
cation and clinical state of the patients. The biopsies were staged according to 
Ludwig et al. (21). For a more refined histological grading and staging of the disea-
se (22, 23), piecemeal necrosis, inflammatory bile duct lesions (affection by 
lymphocytes and degenerative changes of the bile duct epithelium), portal 
infiltrate, lobular infiltrate, fibrosis and copper accumulation were scored on a 
qualitative scale (0-3). An overall histological score combined all individual scores. 
Power calculations had led to a study size of 62 patients. However, after no more 
patients could be recruited during a 6-months period, entry was closed after 50 
patients had entered. With this study size, differences in changes from baseline of 
biochemical values can be detected (two-sided alpha: 0.05; power: 80%) for diffe-
rences of means equalling 0.8 standard deviations. Data are presented as means 
with standard errors, unless indicated otherwise. Laboratory data are expressed as 
multiples of the upper limit of normal (ULN) or percentage change from baseline. 
Changes in laboratory parameters were analysed using Repeated Measurements 
ANOVA, after logarithmic transformation. Symptoms and histological scores were 
compared by non-parametric tests (signed-ranks test and rank-sum test). x2-tests 
were used for qualitative data. A p-value 5: 0.05 was considered significant. All ana-
lyses were performed on an intention-to-treat basis. The study was approved by all 
local Medical Ethical Committees. All patients gave written informed consent. 
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Results 
Entry characteristics in the UDCAlprednisone/azathioprine (U-PA group, n=26) and 
the UDCAlplacebo group (U-PL, n=24) were comparable (table 1). 
Symptoms 
At entry, mean scores for fatigue and pruritus were higher in the U-PL group al-
though the differences were not significant (table 2). No changes in the severity of 
fatigue were observed, neither between nor within the 2 groups. In the U-PA group, 
pruritus decreased although not significantly. A significant difference (p=0.02) 
between the 2 groups was found when changes in pruritus between entry and 12 
months of treatment were compared. All 4 patients with arthralgia in the U-PA 
group noted improvement during treatment and/or deterioration after stopping treat-
ment, while no change was reported by 8 patients with arthralgia receiving U-PL. 
Biochemistry 
In the U-PA group serum APh, AST and IgM improved significantly as compared 
with the U-PL group (all p<0.002). The differences between changes were constant 
Table 1: Patient characteristics at entry. 
U-PA U-PL 
(n=26) (n=24) 
Age (years) 52.7 (8) 52 (10.8) 
Sex (M/F) 3/23 2/22 
APh (x ULN) 2.6 (1.6) 2.8 (1.6) 
AST (x ULN) 1.2 (0.6) 1.2 (0.7) 
ALT (x ULN) 1.5 (0.8) 1.7 (1.4) 
y-GT (x ULN) 4.7 (4) 4.7 (4.7) 
Bilirubin (x ULN) 1 (0.6) 1.1 (0.7) 
Albumin (x ULN) 0.9 (0.1) 0.8 (0.1) 
IgM (x ULN) 1.7 (0.9) 1.9(1.9) 
-P-III-P gIL (n<4.2) 6.1 (3.5) 4.9 (3.0) 
Histological stage 
1/1I/11i/IV 3/7/11/5 1/7/9/6 
Bone mineral density 
g HAlcm2 L2-L4 1.077 (0.221) 1.028 (0.175) 
Femur neck g HAlcm2 0.883 (0.128) 0.819 (0.147) 
Data are expressed as means with standard deviation in parentheses. 
-Measurements performed in 24 patients. 
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Table 2: Scores for fatigue and pruritus. 
U-PA U-PL 
entry 12 months entry 12 months 
Fatigue 20 (18) 20 (18) 27 (19) 27 (16) 
Pruritus 8 (12) 5 (7) 12 (18) 12(15)' 
Means with standard deviations in parentheses . 
• p=0.02, comparison between groups for change in pruritus score. 
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Figure 1. Mean serum alkaline phosphatase (APh), aspartate transaminase (AST) and gM 
during 1 year of UDCA+prednisone/azathioprine (- - -) versus UDCA+placebo tre-
atment (-) and after 3 months of prednisone/azathioprine withdrawal. Data are 
expressed as multiples of the upper limit of normal (ULN). Error bars indicate 
standard errors. Significantly greater decreases occurred in the U-PA group as 
compared to placebo (aI/ p<O.002; rmANOVA after logarithmic transformation). In 
the U-PA group values significantly increased and returned to their pre-treatment 
levels (aI/ p<O.002) at 15 months. 
Figure 2. Means of bilirubin (geometric) and P-II/-P (measured in 24 patients) during 1 year 
of UDCA + prednisone/azathioprine (. - -) versus UDCA + placebo treatment (-) 
and after 3 months of prednisone/azathioprine withdrawal. Data are expressed as 
multiples of the upper limit of normal (ULN) for bilirubin and as percentage chan-
ge from baseline for P-II/-p' Error bars indicate standard errors. No significant 
change in bilirubin occurred. A significantly greater decrease of P-II/-P occurred in 
the U-PA group as compared to placebo (p<O.OOI). 
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Table 3: Histological grading and staging. 
U-PA U-PL 
Entry End p Entry End p 
Disease activity 
Piecemeal necrosis (0-3) 1.14 (0.6) 1 (0.5) 0.35 1.3 (0.7) 1.2 (0.7) 0.71 
Biliary lesions (0-3) 2.1 (0.8) 1.6 (0.9) 0.11 1.9 (1.1) 1.4 (1) 0.14 
Portal infiltrate (0-3) 1.8 (0.6) 1.4 (0.6) 0.01 1.8 (0.6) 1.7(0.7) 0.54 
Lobular infiltrate (0-3) 1.4 (0.5) 0.7 (0.8) 0.006 1.4 (0.7) 1 (0.8) 0.11 
Composite score (0-12) 6.4 (1.6) 4.6 (2.1) 0.002 5.8 (1.7) 4.8 (2.4) 0.11 
Disease stage 
Copper accumulation (0-3) 1.95 (1.3) 1.64 (1.2) 0.13 2(1.1) 2 (1.2) 0.78 
Fibrosis (0-3) 2.23 (1.2) 2.0 (1.1) 0.22 2.55 (0.9) 2.55 (1) 1 
Composite score (0-6) 4.18 (2.2) 3.6 (2.1) 0.05 4.63 (1.9) 4.63 (1.9) 0.86 
Data expressed as means with standard deviation between parentheses. Comparison 
between both groups with respect to change from baseline in the histological scores reve-
aled no significant differences. 
during the whole study period (figure 1). Bilirubin (figure 2) and albumin did not 
change significantly and no differences between the 2 groups were observed. The 
degree of the improvements did not differ between early (HI) and late stage (III-IV) 
disease. These effects were achieved on top of decreases in APh, AST and IgM 
induced by the preceding UDCA treatment as compared with values at the start of 
UDCA (-23%, -44% and -23%, respectively; all p<O.001). 
Three months after cessation of prednisone and azathioprine, APh, AST and IgM 
significantly increased and returned to pre-treatment values, while bilirubin remai-
ned unchanged. 
Biochemical remission, defined as sustained normalisation of AST, IgM and biliru-
bin, and APh " 1.5x ULN), present on at least 2 consecutive follow-up visits, was 
observed in 3 U-PA patients and 1 U-PL patient. In the U-PA group, more patients 
with normalisations of AST (3 vs. 1; p=0.3), APh (APh " 1.5 x ULN: 7 vs. 1; p=0.03) 
and IgM (11 vs. 0; p<0.01) were observed. In none of the patients (8 in each group) 
elevated bilirubin levels normalised. 
After 3 months of treatment, a sustained and significant decrease in P-III-P levels 
(figure 2) was found in the U-PA group as compared with the U-PL group 
(1'<0.001). Abnormal P-III-P levels normalised in 4 of 8 U-PA patients, but in none 
of 5 U-PL patients. 
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Table 4: Non-hepatic events 
U-PA U-PL 
Weight gain 
2.5 kg 10 4 
> 5 kg 8 1 
Cushing face 8 0 
Hypertension* 4 1 
Ecchymosis 3 3 
Hirsutism 2 0 
NIDDM 1 2 
Cytopenia** 2 2 
Infections 2 7 
urinary tract 1 2 
upper respiratory tract 0 2 
sinusitis 0 2 
parotitis 0 1 
spontaneous bacterial peritonitis 1 0 
Gastrointestinal complaints 7 3 
Peritonitis {laparotomy) 0 1 
Partial portomesenterial thrombosis 1 0 
Traumatic vertebral fracture 0 1 
Oedema 2 0 
Angina pectoris 0 1 
Events leading to dose reduction of 
- prednisone 2 0 
- azathioprine 1 1 
Treatment withdrawal 3 1 
* Diastolic pressure increased to ;" 95 mmHg or by 20 ;" mmHg on 2 consecuti-
ve visits. 
** WBC < 2.5x1 09/1 and/or platelets < 70x1 09/1. 
Histology 
Pre- and posttreatment liver biopsies were available in 42 patients (22 U-PA, 20 U-
PL). In 1 patient the entry biopsy was insufficient, 5 patients refused a follow-up 
biopsy and 2 were referred for transplantation. Histological stage according to Lud-
wig et al. did not change significantly in either group. The overall histological score 
decreased significantly in the U-PA group by 2.3 ± 2.4 points (p<0.001) and remai-
ned stable in the U-PL group (-0.9 ± 3; p=0.21). Scores for disease activity, disease 
stage and for lobular and portal infiltrates improved significantly in the U-PA group 
(table 3). These changes, however, did not differ significantly between the 2 study 
groups. 
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Adverse effects 
Forty-four patients were included in the evaluation of bone mineral density; in 6 
patients paired DXA measurements were not available. Twenty-four patients parti-
cipated in a randomised controlled trial evaluating the effect of cyclic etidronate 
and calcium. The main conclusion of this trial, which has been published (20), was 
that in prednisone-treated patients a small but significant difference in lumbar bone 
mass was observed after 1 year in favour of patients receiving etidronate/calcium. 
Non-hepatic events, observed during the study, are summarised in table 4. Evident 
weight gain and hypertension were more frequent in the U-PA group. There was no 
clear difference between the groups in the number of patients showing hepatic 
deterioration using the criteria of Mitchison (8)(table 5). 
Treatment was interrupted in 3 patients treated with U-PA because of persistent 
general malaise (n=2) and spontaneous bacterial peritonitis (n=l) and in 1 U-PL-
treated patient who was referred for transplantation. 
Table 5: Incidence of hepatic deterioration. 
Doubling of bilirubin 
Albumin decrease of > 6 gil 
De novo signs of portal hypertension 
(ascites, variceal bleeding) 
New appearance of cirrhosis 
Accepted for liver transplantation 
Hepatic death 
Number of patients fulfilling 
one or more of these criteria: 
Discussion 
U-PA 
1 
o 
2 
1 
1 
o 
3 
U-PL 
2 
o 
o 
3 
2 
o 
5 
This study shows an additional effect of treatment with prednisone and azathiopri-
ne on itching, on serum markers of liver cell damage, cholestasis, immune activity 
and fibrogenesis and on liver histology in PSC patients who had already been trea-
ted with UDCA for at least 1 year. Our data indicate that side effects of this triple 
therapy are limited. 
The effects of the combined immuno-suppressive treatment were more pronoun-
ced than those reported for azathioprine alone (9, 24). The results of this study are 
in agreement with previous studies, evaluating prednisone monotherapy and com-
bined prednisone/UDCA therapy in previously untreated patients (7, 8). In contrast 
to these studies, however, the observed benefits in this study were achieved on top 
of improvements already obtained with UDCA alone. When the study was initiated 
the standard UDCA dose in our country was 10/mg/kg/day. Current available data 
suggest that this may not be the optimal dose. Since patients of both treatment 
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groups were taking the same UDCA dose, it seems unlikely that this has affected 
the main results. 
The finding that bilirubin, a major prognostic parameter in PBC, remained stable in 
both groups, is readily explained by considering the entry characteristics of the 
patients, the slow progression of the disease and the duration of this study. P-III-P, a 
serum marker of fibrogenesis (25), which has also been reported by several groups 
to be of prognostic significance in PBC (26-29), normalised in 50% of patients recei-
ving triple therapy. In patients receiving UDCA, P-III-P may be a more appropriate 
prognostic marker than bilirubin since UDCA may directly increase bilirubin excre-
tion (28), but does not seem to affect P-III-P levels (30). Obviously, larger trials of 
longer duration are required to establish whether the triple regimen can delay clini-
cal, biochemical and histological disease progression. 
The adverse effect of corticosteroids on bone mass has limited their use in PBC, 
although low-dose prednisone has been shown to be relatively safe in patients with 
non-advanced disease (8, 12). The maximal bone loss during corticosteroid treat-
ment occurs during the first year of therapy (31). Previously we have reported (20) 
that treatment with bisphosphonates can prevent this initial bone loss, which is in 
agreement with studies in other diseases (13-15). Whether this approach will pre-
vent bone loss during long-term corticosteroid treatment remains to be established. 
In the triple treatment group weight gain occurred frequently, which may have been 
related to the relatively high initial prednisone dose. A minority of these patients 
experienced significant cosmetic changes and increased blood pressures. The 
immuno-suppressive treatment was not clearly associated with infections or other 
intercurrent medical problems. As all adverse effects leading to treatment withdrawal 
occurred during the first weeks, diminishing the high induction doses of prednisone 
in future studies should be considered. Other measures such as appropriate dietary 
advice and timely dose adjustments could further decrease the incidence of adverse 
effects. In this context it should be recognised that from the present study no conclu-
sion can be drawn with respect to the relative contribution of the "induction" predni-
sone doses to the overall treatment effect. At least in theory, an induction-main-
tenance regimen could be more effective than regimen without initial higher doses. 
Previous studies, combining UDCA with colchicine, have failed to show additional 
benefit of colchicine (32-34). Additive beneficial effects of methotrexate to UDCA 
have been reported (35, 36) but serious side effects (37), especially interstitial 
pneumonitis, have also been noted (38). The combination of UDCA and metho-
trexate is now the subject of a large controlled trial. 
We conclude that there is a synergistic beneficial effect of low-dose 
prednisone/azathioprine treatment with UDCA in PBC. The short-term benefit/risk 
ratio appears positive and justifies studies to establish the efficacy of long-term 
triple therapy on the incidence of major clinical events of the disease. 
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Summary 
Background/aims: Ursodeoxycholic acid (UDCA) has been reported to be of poten-
tial benefit for primary sclerosing cholangitis (PSG) but little is known about the 
long-term biochemical, histological and radiological efficacy or the optimum fre-
quency of UDGA administration. 
Methods: A 2-year multi-centre randomised controlled trial was initiated to assess 
the effects of UDGA (10 mg/kg/day), given in either single or multiple daily doses, 
on symptoms, serum liver test, cholangiographic and histological findings and the 
occurrence of treatment failure. Liver biopsies were taken and endoscopic retrogra-
de cholangiography (ERG) was performed at entry and after 2 years, follow-up 
examinations were at 3-months intervals. Treatment failure was defined as death, 
liver transplantation, 4-fold increase in serum bilirubin, variceal bleeding, de novo 
ascites or cholangitis. Actuarial survival was compared with predicted survival 
using the revised Mayo natural history model for PSG. 
Results: Forty-eight patients were enrolled. In one case, UDCA had to be disconti-
nued because of gastro-intestinal complaints. No other side-effects were observed. 
After 2 years of follow-up, treatment was not associated with a beneficial effect on 
either symptoms or liver histology. Serum liver tests (alkaline phosphatase, y-gluta-
my I transferase, aspartate aminotransferase) improved significantly in both groups 
while serum bilirubin (which was near normal at entry) and immunoglobulin G 
remained stable. No major changes in radiographic bile duct appearance seemed 
to be present. After 2 years, actuarial survival was 91 % (95 confidence interval 
83%-99%), which is comparable to the predicted 97% survival rate. Treatment failu-
re occurred in 15% of cases. No significant differences in any of the study end-
points (symptoms, serum liver tests, cholangiographic findings, histology, disease 
progression) were found between the 2 groups. 
Conclusions: UDCA is well tolerated in PSG. Significant effects on biochemical 
parameters were found and symptoms, bilirubin and histology did not deteriorate. 
No advantage of a multiple daily dose over a single dose was observed. 
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Introduction 
As a rule, primary sclerosing cholangitis (PSC) is a slowly progressing cholestatic 
liver disease, potentially leading to cirrhosis and liver failure (1, 2). For patients with 
advanced disease, liver transplantation is a therapeutic option. Currently, no effec-
tive medical treatment is available. The relatively few controlled trials did not reveal 
a clear benefit for d-penicillamine (3), methotrexate (4) or colchicine (5). After 
encouraging results were obtained with ursodeoxycholic acid (UDCA) treatment of 
primary biliary cirrhosis (PBC) (6, 7) several uncontrolled (8, 9) and controlled 
(10-12) studies were carried out; the findings suggested beneficial effects of this 
agent on serum liver biochemistry and histology for patients with PSC. Others have 
suggested that the effect of UDCA on survival in PSC is only marginal (13). 
Several studies have indicated that biochemical improvement in patients with cho-
lestatic liver diseases treated with UDCA can be attributed to UDCA enrichment of 
bile (14-17). Previously our group demonstrated that biliary enrichment in patients 
with PBC and PSC is independent of administration as a single-dose or divided 
daily UDCA doses (14). Others, however, have suggested that multiple doses are 
needed to achieve maximum intestinal uptake and biliary UDCA concentration 
(18). Since no information is available on the clinical efficacy of single versus mUl-
tiple daily UDCA administration, we initiated a 2-year randomised controlled trial to 
compare the effects of a single-dose versus 3 divided daily doses of UDCA (10 
mg/kg/day) on symptoms, serum liver test, histology, cholangiographic findings and 
survival in PSC patients. 
Patients and methods 
Patients were selected on the basis of a set of major and minor diagnostic criteria. 
Characteristic findings on endoscopic retrograde cholangiography (ERC) and the 
presence of typical histological lesions (pericholangiolar "onion-skin" fibrosis) were 
considered major criteria. Minor criteria were serum alkaline phosphatase (APh) 2 
x upper limit of normal (ULN) and the presence of inflammatory bowel disease 
(IBD). The diagnosis of PSC was considered definitive if at least one major crite-
rion and one other (major or minor) criterion were present. Exclusion criteria were 
the presence of anti-mitochondrial antibodies, renal failure, malignancy, age < 18 
years, pregnancy, advanced or decompensated disease (defined as Child-Pugh 
class B or C) and evidence of another concomitant liver disease or secondary scle-
rosing cholangitis. Only patients who had never used UDCA or had discontinued 
UDCA at least 3 months before entry were included. Patients taking other poten-
tially disease-modifying drugs, e.g. corticosteroids or azathioprine, were allowed to 
continue this therapy. 
Study design 
This multi-centre trial, performed in 14 centres in The Netherlands, started in Janu-
ary 1993. The study was approved by the ethics committees of all participating 
centres. Patient recruitment was stopped after 2 years because further inclusion of 
patients within the next 6 months seemed unlikely. All patients provided written 
informed consent. Randomisation was performed at 1 centre by opening consecu-
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tively numbered opaque envelopes. UDCA capsules (Ursofalk® 250 mg; Tramedico 
B.V., Weesp, The Netherlands) were administered either in a single dose at bed-
time or in 3 divided doses with meals, at a dose of approximately 10 mglkglday. 
Patients visited the hospital every 3 months for a general clinical examination and 
assessment of symptoms, IBD activity and adverse effects. Blood analyses inclu-
ded serum bilirubin, APh, y-glutamyl transferase (y-GT), aspartate amino transami-
nase (AST) and immunoglobulin G (lgG). Pruritus and fatigue were quantified 
using a self-administered questionnaire. At, and for 5 days after each visit, patients 
were asked to indicate on a 5-point scale the intensity of pruritus and fatigue in the 
morning, afternoon and evening and at night separately. The activity of IBD was 
classified according to the criteria of Truelove and Witts (19, 20). 
Liver biopsy and ERC were performed at entry and after 2 years. All liver biopsies 
were reviewed blind by 2 pathologists (FJWtK and HK). Liver biopsies were staged 
according to Ludwig et al. (21). Furthermore, a numerical scoring system was 
applied for fibrosis (0-5) as the main characteristic of disease stage. Grade of the 
disease was quantified on the basis of bile duct obstruction characterised by cop-
per accumulation (0-3), keratin-7 expression (0-3) (22), portal oedema (0-3) and 
hepatocellular cholestasis (0-3); bile duct lesions characterised by pericholangiolar 
fibrosis (0-1), biliary inflammatory affection (0-3), biliary piecing (0-3) and ductular 
proliferation (0-3); and inflammatory lesions, characterised by portal infiltrate (0-4), 
piecemeal necrosis (0-4), lobular infiltrate (0-3) and focal necrosis (0-4). 
ERC's were reviewed by the trial radiologist (GAJJN) and one of the investigators 
(HRvB), both of whom were unaware of the dose regimen. Radiological features at 
2 years and at entry were compared and scored as deteriorated (increased length 
or number of stenoses), improved (decreased length or number of stenoses) or 
stable (no changes). 
Statistical analysis 
To detect differences of at least 75% of the standard deviation of the main labora-
tory parameters between the single- and the multiple-dose groups, with a signifi-
cance of 0.05 and a power of 80%, a sample size of 60 patients was needed. With 
the numbers achieved, differences of at least 80% of the standard deviation can be 
detected. All analyses were performed on the intention-to-treat basis. The laborato-
ry parameters were expressed as multiples of the ULN. The course of the laborato-
ry parameters was analysed using repeated measurement analysis of variance 
(rmANOVA) after logarithmic transformation of the data. Treatment failure was defi-
ned as death, liver transplantation, 4-fold increase in serum bilirubin, variceal blee-
ding, de novo ascites and cholangitis. Survival and time to treatment failure were 
analysed by the Kaplan-Meier method; the results for the 2 groups were compared 
with the log-rank test. Predicted survival was calculated using the recently revised 
Mayo natural history model (23) and compared with actuarial survival rates. The 
Wilcoxon rank-sum test was used to compare data between groups; within-group 
comparisons were performed with the signed-ranks test. A p-value equal to or less 
than 0.05 was considered statistically significant. 
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Results 
Forty-eight patients were enrolled. In 5 patients (3 single-dose group) the diagno-
sis was not based on cholangiographic abnormalities but on typical histological 
lesions, biochemical abnormalities and the presence of IBO (small-duct PSC). At 
entry, the 2 groups were comparable in terms of clinical, biochemical and histologi-
cal indices (table 1). The mean age was 38.3 years; 71 % of the patients were men 
and 60% had a history of IBO. IBO was in remission in 17 cases, mild in 6 cases 
and severe in another 5 cases. Because of missing data for one patient the intensi-
ty of IBO could not be classified. The mean daily UOCA dose for both groups was 
10.4 mg/kg. 
One patient was lost to follow-up (multiple-dose group). Three patients stopped 
therapy: one (multiple-dose group) because of evidence of autoimmune hepatitis 
for which prednisone was instituted after 3 months (patient censored at that time) 
Table 1: Patient characteristics at entry. 
single dose multiple dose 
(n=23) (n=25) 
Mean age (years) 36.9 (11.6) 39.5 (13.1) 
Sex (M/F) M 171 F 6 M 171 F 8 
Inflammatory bowel disease (n) 15 14 
Histological stage of disease (n) 
1 4 5 
2 3 6 
3 13 13 
4 3 1 
Pruritus (n) 10 10 
Fatigue (n) 15 17 
Concurrent treatment (n) 
Predniso(lo)ne 2 1 
5-aminosalicylic acid 13 10 
Loperamide 1 
Cholestyramine 1 
Bilirubin (ULN) 1.1 (1) 1.0 (0.6) 
Alkaline phosphatase (ULN) 3.9 (2.9) 3.1 (1.6) 
y-GT (ULN) 11 (7.3) 8.1 (4.3) 
AST (ULN) 1.8(1.1) 2.2 (1.7) 
Albumin (ULN) 0.8 (0.1) 0.8 (0.1) 
IgG (ULN) 1.1 (0.3) 1.1 (0.4) 
Data are expressed as means with standard deviation in parentheses. 
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Figure 1: Geometric means of serum bifirubin, alkaline phosphatase (APh), y-glutamyl 
transferase (y-GT), aspartate aminotransaminase (AST) and immuno-globulin G 
(IgG). Data are expressed as multiples of the upper limit of normal (ULN). After 
start of treatment a significant decrease in APh, y-GT and AST was observed. No 
significant differences were found between the 2 treatment groups. 
:~I 
, 
"'" 2.' 
2 
0.4 -
0.2 
Bilirubin 
o,.------____________ --~---__ ~ 
o 1215182124 
Alkaline phosphatase 
I , J , , , 
" 
Aspartate amino transferase 
Singlo dooo 9rOUp 
T , ~ 
Multiple dO~· omup 
" " " Moolhs
..,_. 
"'" 
" 
1.3 -
y-Glutamyllransferase 
T 
Multlplo dose group 
" 
Immunoglobulin G 
Multiple d<>S<l group 
" " " Months 
'" 
~UltiplOd<)$(jgmUp 
L 
. I , J , 
'smOTe dO;'" omup I 
, 
'"T 
0.' Single do"" group 
0 0,7 -.~. -~_~ _______ ~_~_~ 
0 12 
" " " " 
o 
" " " Monlh.
70 
and 2 because of diarrhoea and nausea (1 from the multiple-dose group). In one of 
the latter (multiple-dose group), UDCA therapy was gradually reinstated. No other 
adverse events were reported. In 3 patients in the single-dose group and 2 in the 
multiple-dose group, corticosteroid therapy was instituted because of increased 
activity of IBO. In 1 patient corticosteroids could be discontinued and in another 
case the dose was tapered. In 1 case multiple sclerosis was diagnosed; the patient 
was treated with corticosteroids. During follow-up, cholestyramine therapy was 
instituted in 4 patients (1 single-dose group). 
Throughout the study the scores for pruritus and fatigue were comparable for both 
groups. Changes in severity of symptoms within the groups were not observed. 
Analysis of biochemical, histological and cholangiographic findings 
At entry APh and y-GT were significantly elevated compared to normal and the 
mean levels were higher, although the difference was not Significant, in the single 
Table 2: Histological indices for all patients combined. 
Total group 
entry end p 
Bile duct obstruction 
Copper accumulation (0-3) 1.3 (0.9) 1.3 (1.1) 0.6 
Keratin-7 expression (0-3) 1.3 (0.8) 1.1 (0.9) 0.4 
Portal oedema (0-3) 0.7 (0.7) 0.6 (0.7) 0.7 
Cholestasis (0-3) 0.6 (0.8) 0.5 (0.8) 0.8 
Composite score (0-12) 4 (2.2) 3.6 (2.8) 0.7 
Bile duct lesions 
Pericholangiolar fibrosis (0-1) 0.8 (0.4) 0.7 (0.5) 0.4 
Affection by inflammation (0-3) 1.1 (0.5) 1 (0.4) 0.6 
Biliary piecing (0-3) 1.2 (0.8) 1 (0.8) 0.2 
Ouctular proliferation (0-3) 1.5 (0.8) 1.6 (0.8) 0.4 
Compostte score (0-10) 4.6 (2.1) 4.2 (1.9) 0.6 
Inflammation 
Portal infiltrate (0-4) 1.1 (0.5) 1.3 (0.5) 0.2 
Piecemeal necrosis (0-4) 0.6 (0.8) 0.3 (0.7) 0.07 
Focal necrosis (0-4) 1.6 (1.2) 0.9 (0.6) 0.1 
Lobular infiltrate (0-3) 0.9 (0.8) 0.5 (0.6) 0.1 
Composite score (0-15) 4.2 (2.5) 2.9 (1.8) 0.2 
Data are expressed as means with standard deviation in parentheses. 
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dose group. Serum bilirubin levels were normal or only slightly elevated; 2 patients 
in the single- and 2 patients in the multiple-dose group had bilirubin levels that 
exceeded more than twice the ULN. After 3 months of treatment with UDGA, APh 
had decreased by 31% and 25%, y-GT by 58% and 57% and AST by 33% and 
24% in the single- and multiple-dose groups respectively (all pO.002 compared to 
values at entry; figure 1). Subsequent values remained stable. Serum bilirubin and 
IgG did not change significantly (figure1). There were no significant differences in 
response to therapy between the 2 groups. 
Paired entry and follow-up liver biopsies were available for 36 patients (19 in the 
single-dose group). Six patients refused a follow-up biopsy. One patient died before 
the end of the trial, 1 patient was lost to follow-up, UDGA therapy was discontinued 
in 1 case and 3 patients were referred for transplantation. Histological stage accor-
ding to Ludwig (21) did not change significantly in either group. Almost all histologi-
cal indices improved, although the differences were not significant (table 2). A 
trend towards improvement, however, was noted for piecemeal necrosis, focal 
necrosis and lobular infiltrates. No significant differences were found between the 2 
study groups. 
Paired ERG's were available for 31 patients; 7 patients refused a follow-up ERG (3 
single-dose group), in 6 patients (3 single-dose group) the procedure failed or was 
inadequate for evaluation, 1 patient died and 3 received a liver transplant. Findings 
at ERG suggested deterioration in 10 patients (4 single dose group), stable condi-
tions in 17 patients (11 single dose group) and improvement in 4 patients (1 single 
dose group). 
One patient with small duct PSG died of post-colectomy complications. Serum bili-
rubin remained stable in all other patients with small duct PSG. The histological 
stage increased from stage 2 to 4 in 1 patient with small duct PSG. 
Analysis of survival and 
treatment failure 
During the 2 year follow-up, 3 
patients (1 single-dose group) recei-
ved a liver transplant. One patient 
(single-dose group) died from post-
colectomy complications. In 4 
patients (1 in the single-dose group) 
serum bilirubin increased to at least 
four times the ULN. Two of these 
patients responded favourably to 
endoscopic biliary stenting and one 
to dilatation of dominant bile duct 
strictures. In 1 case intervention fail-
ed and the patient was referred for 
liver transplantation. One patient 
suffered repeated bouts of cholangi-
tis, for which he received repeated 
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Figure 2: Predicted and actuarial trans-
plantation-free survival and time 
to treatment failure (actuarial) for 
all patients. No significant diffe-
rences were found between pre-
dicted and actuarial survival. 
courses of antibiotics and endoscopic therapy. Variceal bleeding, ascites and other 
events indicating progressive disease were not observed. Actuarial transplantation-
free survival at 1 and 2 years was 96% (95% confidence interval (95 CI) 100%-
90%) and 91 % (95 CI 83%-99%), respectively, for both groups. Predicted survival 
was 98% at 1 year and 97% at 2 years, neither of which differed significantly from 
observed survival. Survival without treatment failure was 87% for the single-dose 
group and 83% for the multiple-dose group (not significant) (figure 2). 
Discussion 
The results of the present study show that the effects of treatment with UDCA on 
serum liver test and symptoms in PSC patients are comparable when UDCA is 
administered as a single or as multiple daily doses. Previously our group had found 
that in UDCA-treated patients with cholestatic liver disease, biliary UDCA enrich-
ment is independent of the dose regimen (14). Therefore, the present results seem 
to confirm indirectly the hypothesis that, during prolonged UDCA treatment, multi-
ple daily doses do not result in higher levels of UDCA in the bile acid pool than can 
be achieved with a single daily dose. 
This study confirms previous reports that UDCA is well tolerated by PSC patients 
(8-11,13). 
Like others (8-13), we found prompt improvement in serum liver tests after initiation 
of UDCA therapy. Serum bilirubin remained stable; the (near) normal levels at entry 
may explain why we, unlike others (8, 10, 13), were unable to document a decrea-
se in serum bilirubin following UDCA treatment. 
Our data suggest that UDCA had no clear effect on pruritus and fatigue. This 
observation should be interpreted with caution because this was not a placebo-
controlled trial. 
Although some parameters improved, a consistent beneficial effect on liver histolo-
gy, as reported by others (10, 11), was not apparent. In the single-dose group liver 
inflammatory activity decreased significantly, but this was observed neither in the 
multiple-dose group nor in the 2 groups combined. 
A number of qualitative classifications has been proposed for the cholangiographic 
appearances in PSC (24, 25). A quantitative scoring system has also been develo-
ped (26), based on the grade, length and extent of strictures and the degree of 
dilatation of intrahepatic and extrahepatic bile ducts. In the present study, a serious 
attempt was made to apply this classification system. However, major difficulties, 
including the frequent inability to establish presumed 'normal' bile duct diameters 
and the precise length of strictures or to distinguish dilatation from the pre-existing 
normal calibre, were encountered. In addition, technical variations such as magnifi-
cation and bile duct filling contributed significantly to our eventual failure to assess 
the bile duct abnormalities by means of this quantitative approach, a problem also 
experienced by others (12 and R. Chapman, personal communication). Therefore, 
a crude non-quantitative assessment was made of the cholangiographic features 
and this suggested that there was not a major beneficial effect of UDCA on the 
anatomical bile duct lesions. Moreover, in view of the potential morbidity and the 
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invasive nature of ERC, this procedure does not seem to be suitable for documen-
ting the effects of medical therapies in PSC. 
Recently, the Mayo group reported the results of a randomised placebo-controlled 
trial to evaluate the effects of UDCA in 105 patients; the median and maximum fol-
low-up were 2.2 and 6 years, respectively (13). This study showed absence of a 
favourable effect of prolonged UDCA treatment on symptoms and histology; more 
importantly the authors were unable to detect an effect on the clinically relevant 
endpoints. The 2-year 85% transplantation-free survival rate reported in that study 
is a little lower than the 91 % survival rate observed in the present study. However, 
in contrast to the patients in the Mayo study, the mean serum bilirubin level in our 
patients was near normal, suggesting that our patients had less advanced disease. 
Since our study was not placebo-controlled, the effects of UDCA on transplanta-
tion-free survival were estimated by comparing observed and predicted survival. 
No significant difference was found. However, given the slow progressive nature of 
the disease, the duration of all studies published so far has been fairly short and a 
true benefit of UDCA, possibly restricted to subgroups of patients, remains a 
realistic possibility. 
Could higher doses than used in the Mayo- and in the present study be more 
effective? Although, higher doses of UDCA lead to higher biliary enrichment (27), 
the proportion of UDCA absorbed may decrease with higher doses (18). A recent 
two-year controlled study (12) found that high-dose UDCA (20 mg/kg/day) treat-
ment was well tolerated and had a pronounced, beneficial effect on liver histology. 
Further studies are required to confirm this important finding and to assess the 
long-term clinical efficacy of higher doses. 
In conclusion, we found that serum liver tests improved significantly and the histo-
logy remained stable in PSC patients on UDCA therapy, irrespective of the treat-
ment regimen. A practical implication is that single-dose administration may be 
preferable, since patient compliance is likely to be better when the dose regimen is 
simpler. 
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Abstract 
Background: Traditionally, autoimmune hepatitis (AIH) and primary sclerosing chol-
angitis (PSG) are regarded as separate disease entities. We report on a group of 
patients that suggests the existence of an overlap syndrome of the two conditions. 
Methods: Retrospective analysis of patients of a tertiary referral centre for liver dis-
ease, who fulfil the diagnostic criteria for consecutively AIH and PSG. The diagno-
sis of PSG was based on cholangiographic findings. The diagnosis of AIH was 
based on elevated serum transaminase levels, increased immunoglobulin G levels 
and the presence of serum auto-antibodies, in combination with liver histology 
showing interface hepatitis and a predominantly Iymphoplasmacytic infiltrate. The 
diagnosis was tested against a diagnostic scoring system defined by an interna-
tional consensus group in 1993. 
Results: Diagnosis of the overlap syndrome was established for eight patients. 
Four patients presented with features of AIH and in four cases PSG was diagnosed 
first. Seven patients also suffered from inflammatory bowel disease. All patients 
responded to immunosuppressive therapy, in three cases long-term remission was 
achieved. During prolonged follow-up two patients underwent liver transplantation. 
Conclusions: Patients with overlapping features of AIH and PSG may be more 
common than is currently assumed. Recognition of this syndrome is of clinical sig-
nificance because the therapeutic consequences are so important. Our findings 
support the concept that AIH and PSG are phenotypes of an immune-mediated 
liver disease with varying degrees of biliary and parenchymal involvement. 
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Introduction 
Autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary 
biliary cirrhosis (PBG) are usually regarded as separate disease entities. On the 
basis of clinical, biochemical, sero-immunological, histological and radiological cri-
teria, a clear distinction between these conditions can readily be made in the majo-
rity of cases. However, AIH, PSG and PBG also have many features in common. In 
particular, autoimmune-mediated necro-inflammatory damage of hepatocytes and 
bile ducts seems to be of primary pathogenic importance (1-5). 
In other autoimmune diseases the occurrence of patients with overlap syndromes 
has been clearly established (6). In recent years, syndromes with overlapping 
features of AIH and PBG have also been recognised increasingly (7-11). Further-
more, the simultaneous presence of AIH and PSG has been described, especially 
in children (12) but also in a number of adults (13-16). Recent review articles, 
however, (4, 5, 17) do not refer to this syndrome, illustrating that it is still believed 
to be rare. Our senior authors (HRvB; SWS) have noticed over a 20-year period a 
change in the phenomenology of AIH, in particular an increase in incidence in 
young males, often with cholestatic features and regular occurrence together with 
PSG. To verify this clinical impression, a retrospective study was initiated. We 
report here our single-centre experience with eight patients with an AIH and PSG 
overlap syndrome. 
Patients and methods 
A survey was performed to identify cases of the concomitant diagnoses of AIH and 
PSG in our centre since 1980. The diagnosis PSG was based on cholangiography 
showing (multi)focal stricturing of intrahepatic and/or extrahepatic bile ducts with 
intervening normal or dilated segments, producing a beaded bile duct appearance. 
Originally, cholangiograms were studied by a senior radiologist with a special inte-
rest in endoscopic retrograde cholangiography (ERG); for the purpose of this study 
all cholangiograms were reviewed by the first author. The diagnosis of AIH was 
based on the finding of at least three-fold elevations in serum transaminase activi-
ties, elevated concentrations of IgG or y-globulins and positive tests for antinuclear 
antibodies (ANA), smooth muscle antibodies (SMA) or liver-kidney microsomal 
antibodies in combination with liver histology showing moderate or severe chronic 
active hepatitis with interface hepatitis and a predominantly Iymphoplasmacytic 
infiltrate. Patients were assumed not to have AIH if there was evidence for viral 
hepatitis or some other concomitant liver disease, except for PSG, and if antimito-
chondrial antibodies (AMA) were present. PSG was not diagnosed if bile duct 
abnormalities could possibly be attributed to such causes as previous bile-duct 
surgery, ischaemia or portal vein thrombosis. Furthermore, a numerical scoring 
system for the diagnosis AIH, proposed by an international group of experts during 
a consensus meeting in 1993 (18), was used to test the diagnosis retrospectively. 
In accordance with others, who applied this diagnostic system to patients with PSG 
(19), scores were obtained before therapy and IBD was not considered an autoim-
mune disorder. Furthermore, despite the fact that "biliary lesions" are to be expec-
ted in patients with PSC, the score was decreased by one point in cases with his-
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tological features such as cholangiolitis, pericholangiolar ("onionskin") fibrosis and 
bile duct proliferation. 
Data relevant for this study were extracted from patient files and data-banks of the 
radiological, pathological, biochemical and immunological departments. All patients 
were followed until December 1997 or until death. 
Determination of serum bilirubin, aspartate aminotransaminase (AST), alanine 
aminotransaminase (ALT), alkaline phosphatase (APh), immunoglobulin G (lgG) 
and y-globulins was performed by means of standard automated procedures. 
Immunofluorescence techniques were used to detect auto-antibodies. Perinuclear 
antineutrophile cytoplasmic antibodies (pANCA) were detected on granulocytes, 
ANA on Hep2 cells, AMA on mouse and rat kidney cells and SMA on rat stomach 
cells. Markers for hepatitis A, Band C were determined by standard commercially 
available tests. 
Case reports 
Case one: 
In 1977 this man underwent chole-
cystectomy at the age of 50. At that 
time he was jaundiced. In 1982, at 
the age of 55, he was admitted 
elsewhere with jaundice. Endosco-
piC retrograde cholangiography 
(ERC) revealed multiple intrahepa-
tic biliary stenoses and two strictu-
res in the common bile duct; PSC 
was diagnosed. Common bile duct 
stenoses were considered to be the 
most likely cause of the jaundice 
and side-to-side hepatico-jejunosto-
my was carried out. Postoperative 
T-drain cholangiography confirmed 
the presence of two common bile 
duct strictures and several intrahe-
patic strictures (figure 1). Histologi-
cal examination of a biopsy speci-
men of the common bile duct was 
Figure 1: 
T-tube cho-
langiography 
(case 1) 
showing 
intrahepatic 
and extrahe-
patic bile duct 
strictures. 
The wall of 
the common 
bile duct is 
irregular and 
small diverti-
cula are pre-
sent near the 
strictures 
(lower two 
arrows). 
consistent with sclerosing cholangitis. Five months after the surgical procedure he 
was readmitted for persistent jaundice. Clinical evidence of inflammatory bowel dis-
ease (IBD) was not present. Serum bilirubin (117 f!molll, normal < 16), transamina-
ses (AST 432 U/I, ALT 337 U/I; normal < 30) and IgG (53.1 g/I, normal < 16 g/I) 
were elevated and SMA were present. HLA typing revealed the presence of the 
B8-DR3 haplotype. A liver biopsy showed extensive fibrosis, portal and lobular 
lymphocytic and plasma cellular infiltrates and periportal piecemeal necrosis (figu-
re 2). AIH in association with PSC was diagnosed and the patient received predni-
sone/azathioprine combination therapy. Full clinical remission, but incomplete bio-
80 
Figure 2: Liver biopsy (case 1). 
A shows an enlarged portal triad with a predominantly Iymphoplasmacytic infiltra-
te with an ill-defined limiting plate and (top) inflammatory cells infiltrating into the 
adjacent parenchyma. Original magnification x 20 
B Portal Iymphoplasmacytic infiltrate expanding into the liver lobulus with piece-
meal necrosis. Original magnification x 40. 
chemical response (normal bilirubin and IgG, transaminases ± 1.5 x upper limit of 
normal) followed. In subsequent years, despite maintenance treatment with predni-
sone and azathioprine, episodic hepatitis flares occurred and a predominantly 
cholestatic biochemical profile emerged. In 1990 ursodeoxycholic acid (UDCA) was 
added to the therapeutic regimen. Gradual disease progression necessitated liver 
transplantation in 1992. Colonoscopy before this procedure revealed abnormalities 
indicative of long-standing, inactive IBD. At present the patient is doing well. 
Case two: 
This male patient was diagnosed 
with AIH at the age of 7 in 1985. 
Serum bilirubin was 52 ~mol/I, AST 
364 U/I, ALT 115 U/I and IgG 29 g/1. 
ANA (titre> 1 :640) and low titres of 
SMA were detected. A liver biopsy 
showed chronic active hepatitis with 
features of AIH (figure 3). Treatment 
consisted of 5 mg prednisone/day; 
complete biochemical remission 
was achieved after one year. In 
1987 he was reassessed because 
of rectal blood loss. Colonoscopy 
and biopsy specimens showed left-
sided ulcerative colitis which was 
treated with salazopyrine. Subse-
Figure 3: Liver biopsy (case 2) 
Portal area with moderately den-
se Iymphoplasmacytic infiltrate 
and periportal piecemeal necro-
sis. Original magnification x 40. 
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quently, while on maintenance treat-
ment with prednisone, liver biochemi-
cal tests showed mild fluctuations. In 
1993 azathioprine was initiated 
because the transaminase levels 
were increased 4-5 fold. In 1996 he 
was referred to our department. 
Serum bilirubin (41 Ilmol/l) and APh 
(630 U/I, n < 75) were increased. 
Intrahepatic bile duct abnormalities 
characteristic of PSG were found at 
ERG (figure 4). The liver biopsy 
showed marked fibrosis, bile duct pro-
liferation and minimal inflammatory 
activity. UOGA therapy was started 
three months later. 
Results 
Figure 4: 
Endosco-
pic retro R 
grade 
cholan-
giogram 
(case 2) 
showing 
multiple 
areas of 
intrahepa-
tic stric-
tures and 
ductal 
dilatation. 
In the period 1980-1997 eight patients who fulfilled the diagnostic criteria for both 
AIH and PSG were identified. The age at presentation with either one of these con-
ditions varied from 7 to 54 years (mean 24.7). An overlap syndrome was diag-
nosed after intervals varying from 6 months to 11.5 years (mean 6.3 years). The 
duration of follow-up ranged from 1 to 16.8 years. Seven patients had concomitant 
IBO; in the one remaining case endoscopic investigations were not performed. 
Four patients (2 male, 2 female), mean age 16 years (range 7-22), were initially 
diagnosed with AIH (table 1). In all cases the serum transaminase levels were ele-
vated at least ten-fold (mean 18 times the upper limit of normal, IgG or y-globulin 
concentrations were raised, SMA andlor ANA were detected and the liver biopsy 
showed interface hepatitis with a Iymphoplasmacytic infiltrate. Marked biochemical 
improvement was observed after treatment with prednisone and azathioprine 
(table 2). Mainly because a predominantly cholestatic biochemical profile emerged 
during follow-up, ERG was performed at intervals after the initial diagnosis, varying 
from 5.9 to 11.5 years (mean 8.9 years). 
Four patients, all men with a mean age of 33.5 years (range 20-54), were initially 
diagnosed with PSG. Liver histology showed pericholangiolar fibrosis in one case; 
pANGA were detected in 2 cases and 3 suffered from concomitant IBO. AIH was 
diagnosed after a mean interval of 3 years (range: 0.5-5.8). 
Of the patients in whom PSG was diagnosed first, one patient (number 3) exhibited 
the classical features of AIH: transaminases elevated ten-fold, IgG 49 gil, high 
titres of SMA and histologically severe chronic active hepatitis. PSG had been 
diagnosed elsewhere six years earlier; in the course of time he exhibited persis-
tently elevated transaminases and underwent an episode of severe hepatitis, which 
resolved spontaneously. In retrospect, the diagnosis of AIH could have been esta-
blished six years earlier. Another patient (number 6) developed liver failure with 
variceal bleeding and ascites when corticosteroids were withdrawn following colec-
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Table 1: Patient characteristics at presentation and laboratory findings at the time of diagnosis of AIH. 
patient sex age IBD initial diagnostic interval AIH score histology IgG (gil) y-globulin SMA ANA 
diagnosis PSG-AIH (years) (gil) 
1 M 7 UG AIH 11 16 ifh,f 29.4 1 :10 >1 :640 
2 M 14 UD AIH 11.5 17 ifh,f 49.2 1:40 1:80 
3 M 20 UG PSG 5.6 17 pcf, ifh 49.4 1:320 negative 
4 F 21 UG AIH 5.9 17 ifh,f 40 negative 1 :2560· 
5 F 22 GD AIH 7.3 18 ifh 30 1 :320- 1:80-
6 M 23 UG PSG 2.9 15 ifh,c 34.8 negative 1 :180 
7 M 37 no PSG 5.8 15 ifh,f 20.9 negative 1 :2560 
8 M 54 UD PSG 0.5 17 ifh,f 53.1 1:80 1:40 
18D: inflammatory bowel disease; UC: ulcerative colitis; CD Crohn's disease; UD undetermined colitis. 
AIH score: score according to international autoimmune hepatitis group before immunosuppressive treatment (18). A score> 15 indicates 
"definite" AIH and a score of 10 to 15 indicates "probable" AIH. 
ifh: interface hepatitis; pet: pericholangiolar fibrosis; f:fibrosis; c:cirrhosis 
* data 3-4 years after diagnosis AIH 
Table 2: Serum liver tests and IgG/y-globulins during the first year of immunosuppressive treatment. 
bilirubin (~mol/l) AST (U/I) APh (U/I) IgGly-glob (gil) 
Patient start 1 month 1 year start 1 month 1 year start 1 month 1 year start 1 month 1 year 
1 52 10 9 364 38 72 458 146 397 29.4 
2 22 19 18 470 30 172 338 223 458 49.2-
3 459 148 29 410 81 45 166 151 95 49.4 36 13.9 
4 123 n.a. 10 918 149 12 35 33 17 40- 18-
5 46 11 15 348 82 97 135 80 97 34-
6 307 450 36 750 332 112 87 100 122 34.8 19 21 
7 54 27 11 303 23 14 117 55 120 23.2 12.8 9.9 
8 117 20 9 432 99 106 119 90 82 53.1 21.6 28.4 
reference values: APh < 75 U/I; AST < 30 U/I; bilirubin < 12 ~moIA; IgG < 16 gil; y-globulins 9-18 gil 
- 'Y-globulins 
~--
--- ----
tomy for ulcerative colitis. Renewed immunosuppressive treatment resulted in com-
plete clinical and biochemical remission. Another patient (number 7) developed 
AIH when the corticosteroids, which he had received for 8 weeks in the context of 
a controlled clinical trial for PSG, were tapered off. The fourth patient (number 8; 
case 1) remained jaundiced after hepatico-jejunostomy for common bile duct stric-
tures. During immunosuppressive treatment bilirubin, transaminases, APh and 
immunoglobulins normalised or decreased significantly (table 2). 
Five patients, four with an initial diagnosis of PSG, received UDGA during the cour-
se of their disease at various intervals after the date of diagnosis. This treatment 
appeared to result in slight improvements in the serum liver tests in some cases. 
ERG revealed bile duct changes characteristic of PSG in all cases. Mild abnormali-
ties of both intrahepatic and extrahepatic ducts were found in 3 patients while only 
the intrahepatic ducts were affected in 2 patients. In 2 patients marked intrahepatic 
bile duct deformities were found, one was associated with intrahepatic stones 
while the extrahepatic ducts appeared to be normal. Dominant strictures were 
observed in one patient (no. 8, case 1). 
Despite an initially favourable therapeutic response to immunosuppressive therapy, 
one patient initially diagnosed with AIH (no. 5) and one with an initial diagnosis of 
PSG (no. 8) had slowly progressive disease and received a liver transplant after 7 
and 9 years, respectively. The remaining five patients are alive and are still being 
followed. In three cases long-term biochemical remission was achieved with conti-
nued immunosuppressive treatment. 
Discussion 
In this report 8 patients with an overlap syndrome of AIH and PSG are described. 
In view of the number of cases reported in the literature (table 3) this represents a 
relatively large group. It is noteworthy that four more patients have been identified 
with AIH who had marked cholestatic liver function test abnormalities, negative test 
results for AMA, and histologically chronic active hepatitis with ductular changes, 
pericholangiolar fibrosis and copper deposits. A diagnosis of PSG, however, could 
not be made because cholangiography was not performed. 
Specific referral patterns and increased diagnostic awareness in recent years may 
have contributed to the number of cases reported here. The prevalence of the 
overlap syndrome among patients with AIH remains to be established because 
none of the studies reported, including the present one, included cholangiography 
in all cases. Among children with AIH a prevalence of 27% was reported, but also 
in this study cholangiography was not performed uniformly (20). The prevalence of 
AIH among patients with PSG was assessed by Boberg et al. (19), who applied the 
1993 AIH scoring system to a group of 114 PSG patients. Two (2%) patients were 
classified as "definite" AIH and 38 (33%) as "probable" AIH. 
Establishment of the diagnosis of AIH is difficult since there is no single diagnostic 
test or validated set of criteria. This applies specifically for patients with a concomi-
tant liver disease. The diagnostic aspects of AIH were addressed by an internatio-
nal forum of experts during a consensus meeting in 1993. Their efforts resulted in 
a diagnostic system, which, however, still may not be ideal and should be further 
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improved (21). In our centre we rely mostly on the 
positive criteria of more than 3-10 fold elevations of 
serum transaminases, two-fold elevation of IgG or 
y-globulins, presence of auto-antibodies and com-
patible liver histology. Negative factors such as 
alcohol use, positive viral serology, hepatotoxic 
medication and biliary lesions on biopsy are clearly 
considered, but we do not attribute a decisive signi-
ficance to these factors. The report of the 1993 
meeting (18) states that patients with biliary chan-
ges identified either histologically or by cholangio-
graphy should not be assumed to have AIH. This 
point of view should be modified in the light of 
cumulating evidence that true overlap syndromes 
do occur (21). With these reservations in mind, our 
patients were evaluated according to the 1993 sys-
tem. The scoring system was applied conservatively 
and resulted in scores indicating "definite" AIH for 6 
patients and "probable" AIH for 2. Both of the latter 
patients exhibited a complete response to therapy. 
The observed response to immunosuppressive the-
rapy in the other cases further strengthens our 
belief that all of our patients had AIH. 
When the clinical features of patients in the present 
series are compared with those of previously repor-
ted adult patients (table 3) with AIH-PSG overlap, 
several similarities are found: percentage males is 
75% versus 63% in the literature, mean age at pre-
sentation 25 versus 27 years and prevalence of IBD 
88% versus 70%, respectively. With respect to other 
laboratory, histological and radiological characteris-
tics, these patients seem to be very similar. The 
presently available cumulative experience indicates 
that the AIH-PSG overlap syndrome is mainly, but 
not exclusively, a disorder encountered in children 
and young adults, with a predominance of males. In 
the majority of cases the overlap syndrome is asso-
ciated with ulcerative colitis or Grohn's disease. 
The therapeutic response to immunosuppressives 
can be excellent. Our experience as well as that of 
others (14-16) indicates that proper therapy can 
lead to complete remission of disease activity and 
indeed may be life-saving. However, our experience 
seems to be in accordance with that of earlier 
reports (12, 13, 22, 23) suggesting that the thera-
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peutic benefit for patients with an overlap syndrome may be less than for those 
with "genuine" AIH. In fact, two of our patients needed a liver transplant 7-9 years 
after the start of immunosuppressive therapy. This finding is in contrast to current 
results for genuine AIH (24). 
The cause of AIH and PSC is unknown. Most findings seem to indicate that these 
disorders may develop in patients with a genetic susceptibility. Human leukocyte 
antigen (HLA) studies have shown that both disorders are closely associated with 
B8, DR3-positive haplotypes (19, 25) and with the DRB3 allele DRB3*01 01, which 
encodes for DR52a (26, 27). The results of detailed HLA typing have not been 
reported for patients with the overlap syndrome and this therefore requires further 
study. The many similarities between the clinical, histological, genetic and immuno-
logical features of AIH and PSC (19, 28) and the existence of an overlap syndrome 
may suggest that these conditions represent phenotypic expressions of a common 
underlying process with aberrant autoreactivity. The role of IBD within this concept 
is even more speculative. IBD is associated with both PSC (4, 5, 29) and AIH (22) 
and the majority of overlap patients had IBD. In theory, IBD could be another phe-
notypic manifestation of a common underlying disease process. On the other hand 
IBD could be a condition that facilitates the development of AIH and PSC. 
In conclusion, we report on eight patients with an overlap syndrome of AIH and 
PSC, which brings the total number of reported cases to 27. Although the true pre-
valence remains to be established, our experience suggests that this entity may be 
less rare than currently assumed. Clinicians should be well aware of this syndrome 
since recognition of these cases can have major therapeutic implications. 
Acknowledgement 
We gratefully acknowledge the help of Pieter E Zondervan and Monica Seijbel of 
the Department of Pathology of the University Hospital Rotterdam. 
86 
References 
1. Kaw M, Silverman WB, Rabinovitz M, Schade RR. Biliary tract calculi in primary sclero-
sing cholangitis. Am J Gastroenterol 1995;90:72-5. 
2. Lo SK, Fleming KA, Chapman RW. A 2-year follow-up study of anti-neutrophil antibody 
in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and 
ursodeoxycholic acid treatment. J Hepatol 1994;21 :974-8. 
3. Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA, Dickson ER, et al. M4 
and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic ac-
tive hepatitis: epitopes or epiphenomena? Hepatology 1992; 16:1128-36. 
4. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33. 
5. Harnois OM, Lindor KD. Primary sclerosing cholangitis: evolving concepts in diagnosis 
and treatment. Dig Dis 1997;15:23-41. 
6. Bernhard GC. Mixed connective tissue disease and other overlap syndromes. In: Katz 
WA, ed. Diagnosis and management of rheumatic diseases. 2nd ed. Philadelphia: J.B. 
Lippincot Company, 1988:530-4. 
7. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, Palmer JM, 
et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome 
of autoimmune cholangitis. Gut 1994;35:260-5. 
8. Ben-Ari Z, Dhillon Ap, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of 
autoimmune chronic active hepatitis. Hepatology 1993;18:10-5. 
9. Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: the result of 
consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 
1994;107:1839-43. 
10. Flora K, Benner K, Lee R, Fennimore S. Primary autoimmune cholangitis as an early 
variant of primary biliary cirrhosis. Hepatology 1994;20:152A. 
11. Chazouilleres 0, Montembault S, Poupon R. Primary biliary cirrhosis (PBC)-autoim-
mune hepatitis (AH) overlap syndrome: Clinical features and response to therapy. 
Hepatology 1996;24:167A. 
12. el-Shabrawi M, Wilkinson ML, Portmann B, Mieli-Vergani G, Chong SK, Williams R, 
Mowat AP. Primary sclerosing cholangitis in childhood. Gastroenterology 
1987;92:1226-35. 
13. Minuk GY, Sutherland LR, Pappas SC, Kelly JK, Martin SE. Autoimmune chronic active 
hepatitis (lupoid hepatitis) and primary sclerosing cholangitis in two young adult fema-
les. Can J Gastroenterol 1988;2:22-27. 
14. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence 
of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient 
with ulcerative colitis. Dig Dis Sci 1992;37:1606-11. 
15. Lawrence Sp, Sherman KE, Lawson JM, Goodman ZD. A 39 year old man with chronic 
hepatitis. Semin Liver Dis 1994;14:97-105. 
16. Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, Meyer zum 
Buschenfelde K. Evidence for an overlap syndrome of autoimmune hepatitis and pri-
mary sclerosing cholangitis. J HepatoI1996;24:699-705. 
17. Mitchell SA, Chapman RW. Review article: the management of primary sclerosing cho-
langitis. Aliment Pharm Therap 1997;11 :33-43. 
18. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. 
Hepatology 1993;18:998-1005. 
19.( Boberg KM, Fausa 0, Haaland T, Holter E, Mellbye OJ, Spurkland A, Schrumpf E. 
! Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 
87 
114 primary sclerosing cholangitis patients according to a scoring system for the diag-
nosis of autoimmune hepatitis. Hepatology 1996;23:1369-76. 
20. Gregorio GV, Portmann B, Reid F, Donaldson PI. Doherty DG, McCartney M, Mowat 
Ap, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 
1997;25:541-7. 
21. Mackay IR. Toward diagnostic criteria for autoimmune hepatitis. Hepatology 
1993;18:10068. 
22. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative 
colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-
31. 
23. Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML. An atypical presentation for primary 
sclerosing cholangitis. Dig Dis Sci 1997;42:2009-16. 
24. Schvarcz R, Glaumann H, Weiland 0. Survival and histological resolution of fibrosis in 
patients with autoimmune chronic hepatitis. J Hepatol1993;18:15-23. 
25. Donaldson PI. Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. 
Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 
and A 1-B8-DR3 are independent risk factors. Hepatology 1991 ;13:701-6. 
26. Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, 
McFarlane IG, et al. Allelic sequence variation in the HLA class II genes and proteins in 
patients with autoimmune hepatitis. Hepatology 1994; 19:609-615. 
27. Boberg KM, Schrumpf E, Fausa 0, Leivestad T, Vartdal F, Spurkland A. Increased fre-
quency of HLA-DRB3'01 01 (DR52a) associated DQA 1 ,DQB1 haplotypes in primary 
sclerosing cholangitis (PSC). J Hepatol1994;21 (suppl):S71. 
28. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary scle-
rosing cholangitis. Gastroenterology 1980;79:200-6. 
29. Mitchell SA, Chapman RW. Review article: the management of primary sclerosing cho-
langitis. Aliment Ph arm Therap 1997;11 :33-43. 
88 
CHAPTER 7 
BUDESONIDE OR PREDNISONE IN COMBINATION 
WITH URSODEOXYCHOLIC ACID IN PRIMARY 
SCLEROSING CHOLANGITIS: A RANDOMIZED 
DOUBLE-BLIND PILOT STUDY 
Hubert JF van Hoogstraten 1, Frank P Vleggaar1, Greet J Boland2, Werner van 
Steenbergen3, Pieter Griffioen4, Wim CJ Hop5, Jan van Hattum2 Gerard P van 
Berge-Henegouwen2, Solko W Schalm 1 and Henk R van Buuren 1, representing 
the Belgian-Dutch PSC study group. 
Dept. of Gastroenterology and Hepatology, University Hospitals 1 Rotterdam, 
2 Utrecht, 3Leuven, The Netherlands & Belgium; 4Dept. of Clinical Chemistry, 
5Dept. of Epidemiology and Biostatistics, University Hospital Rotterdam, 
The Netherlands. 
Submitted Am J Gastroenterol 
89 
Summary 
Introduction: PSC has characteristics of an (auto)immune-mediated disease; 
however, few studies have evaluated corticosteroid therapy for this disorder. 
Methods: We performed an 8-week double-blind randomised pilot study to assess 
the effects of additional treatment with 9 mg budesonide (n=6) versus 3 mg bude-
sonide (n=6) versus 10 mg prednisone (n=6) in patients who had been treated with 
UDCA (mean dose 12 mg/kg/day) for at least five months without achieving bio-
chemical remission. Pruritus and fatigue were evaluated using visual analogue 
scales. Serum liver biochemistry was measured every four weeks. At entry and at 
the end of the trial, adrenocorticotrophic hormone (ACTH) and dehydroepiandro-
sterone (DHEA) were measured to assess effects on the pituitary-adrenal axis. 
Duodenal bile was collected for assessment of biliary corticosteroid activity. 
Results: Pruritus decreased significantly more in the prednisone group compared 
to both the 3 mg and the 9 mg budesonide groups (p<0.05). Alkaline phosphatase 
(mean: -23.4%; p=0.03) and immunoglobulin G (mean: -16.2%; p=0.04) decreased 
in the prednisone group, while bilirubin, y-glutamyl transferase, aspartate amino-
transaminase and alanine aminotransaminase did not change significantly. No sig-
nificant clinical and liver biochemical changes were observed in the 3 mg and 9 mg 
budesonide groups. Significantly larger drops in serum ACTH were found in the 10 
mg prednisone group (-40.7%; p=0.04) and 9 mg budesonide group (-36.6%; 
p=0.02) compared to the 3 mg budesonide group (+19.0%). No significant differen-
ces in percentage change in baseline values for DHEA between the three treat-
ment arms were found. Mononuclear cell proliferation assays did not demonstrate 
corticosteroid activity in bile. Autoimmune hepatitis was observed in one case (9 
mg budesonide) when corticosteroids were tapered off. 
Conclusion: The results of this pilot study suggest only minor beneficial short-term 
effects of prednisone but not budesonide on symptoms and serum liver tests in 
UDCA-treated PSC patients. 
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Introduction 
The aetiology of primary sclerosing cholangitis (PSG) is unclear. An (auto)immune 
background is suggested (1,2) by the strong association between PSC and inflam-
matory bowel disease (IBO) (3,4), the presence of perinuclear antineutrophil cyto-
plasmic antibobodies (pANCA) (5-8) and an increased prevalence of HLA B8 OR3 
OR52a genotypes (9-11). Furthermore, an overlap syndrome between autoim-
mune hepatitis (AIH) and PSC has been described (12-14). 
Few studies have evaluated the effects of corticosteroid treatment in PSC. Predni-
sone therapy has only been assessed in open-label studies (15,16). The use of 
corticosteroids in cholestatic liver disease has been discouraged because of 
potential side-effects, in particular osteoporosis (17). Systemic side-effects of corti-
costeroids may be avoided by replacing prednisone by budesonide, which is a 
potent corticosteroid with a high first-pass effect (18), resulting in low systemic 
availability and potentially fewer side-effects (19). 
Improvements in serum liver function tests and histology have been observed follo-
wing ursodeoxycholic acid (UOCA) monotherapy in PSC (20-22). Although effects 
on disease progression were absent after 2 years of treatment (23), the drug is still 
being used extensively in PSC. In view of these facts, a double-blind randomised 
pilot study was initiated to evaluate the efficacy and safety of budesonide and 
prednisone in addition to UOCA maintenance therapy for PSC patients. 
Patients and methods 
A total of 104 PSC 
patients was screened 
for eligibility; a flow 
diagram according to 
the CONSORT state-
ment (24) is given in 
figure 1. Reasons for 
not participating are 
listed in table 1. Eigh-
teen patients were 
recruited. The diagno-
sis of PSC was based 
on characteristic fin-
dings on endoscopic 
retrograde cholangio-
graphy (ERC) (25) in 
17 cases. Typical his-
Table 1: Reasons for not randomising a patient. 
patient refused 
use of immunosuppressive medication 
biochemical remission 
no UOCA treatment 
previous cholecystectomy 
biliary stent 
Child-Pugh score> 6 
presence of malignancy/other severe disease 
PSC associated AIH 
age > 65 years 
AIH: autoimmune hepatitis. 
13 
13 
33 
8 
4 
2 
3 
6 
1 
3 
tological lesions (pericholangiolar "onion-skin" fibrosis) (26) in combination with 
both a serum alkaline phosphatase (APh) level elevated to more than twice the 
upper limit of normal (ULN) and the presence of IBO led to the diagnosis of PSC in 
one patient. Prior to the study, all patients had been treated with UOCA (mean 
dose 12 mg/kg body-weighVday) for at least five months, without achieving bioche-
mical remission, defined as normalisation of APh, aspartate aminotransaminase 
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(AST) and alanine amino-
transaminase (ALT). Exclu-
sion criteria were: age> 65 
years, use of immunosup-
pressive drugs such as cor-
ticosteroids, azathioprine, 
cyclosporine or metho-
trexate, pregnancy, eviden-
ce of PSC-associated AIH, 
previous cholecystectomy, 
presence of a biliary stent 
and cirrhosis with a Child-
Pugh score> 6 (27). 
1 1 
1~:r=~1 1~:r=~1 1~:r=~1 
1 1 1 1 1 1 
1:=-=-=·::::;1 I~-=~'=~'-=·::::;1 1 .-.~.,-. 1 
Figure 1: Study profile. 
Patients were randomised by assigning consecutive treatment numbers, which cor-
responded to the trial medication. Patients were randomised to take 10 mg/day 
prednisone (two 5 mg tablets of prednisone and three placebo capsules Budeno-
falk®), 3 mg/day budesonide (one 3 mg Budenofalk® capsule, two placebo capsu-
les and two placebo tablets of 5 mg prednisone) or 9 mg/day budesonide (three 3 
mg Budenofalk® capsules and two placebo tablets of 5 mg prednisone) for eight 
weeks. Verum and placebo medication was of identical appearance. Treatment with 
UDCA was continued. Three blocks of six patients were generated. In each block, 
the three treatment options were equally and randomly distributed. One block of six 
treatment numbers was allocated to each participating centre: University Hospitals 
Rotterdam, Utrecht and Leuven. The randomisation list was generated by Allpha-
med, Goettingen, Germany; the medication was packed accordingly. Follow-up 
data were collected every 4 weeks. Blood analysis including bilirubin, APh, y-gluta-
my I transferase (y-GT), AST, ALT, immunoglobulin G (lgG), immunoglobulin M 
(lgM), albumin and prothrombin time was performed by standard automated proce-
dures. Separation of APh isoenzymes was performed by agarose gel electrophore-
sis (Titan Gel®, Helena Laboratories, Gateshead, United Kingdom). Quantitation of 
APh isoenzyme fractions was performed by computerised scanning techniques 
(Sharp, JX330P). At baseline and after eight weeks, blood was drawn to assess 
adrenocorticotrophic hormone (ACTH) and dehydroepiandrosterone (DHEA) after 
30 minutes of bedrest, at 09.00 a.m., to determine effects on the pituitary-adrenal 
axis. The severity of pruritus and fatigue was quantified with visual analogue scales 
(VAS), starting one week before administration of the study medication. Patients 
were asked to indicate daily the severity of pruritus and fatigue on a 10 cm scale 
during the complete study period. After the 8-week study period all patients re-
ceived treatment with 5 mg prednisone per day; subsequently, prednisone was 
tapered off in three weeks. 
Poor compliance was defined as taking less than 90% of the study medication. The 
study was approved by the Medical Ethics Committees of each of the three partici-
pating hospitals and all patients gave written informed consent. All assessments, 
except the quantitation of APh isoenzymes, were performed before the randomisa-
tion code was broken. 
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Collection of bile and determination of biliary corticosteroid activity 
Bile was collected using duodenal intubation under fluoroscopic control at entry 
and on the last day of treatment. Gall-bladder contraction was induced by intrave-
nous injection of 2 g of ceruletide (Takus®, Pharmacia & Upjohn GmbH, Erlangen, 
Germany). A maximum dose of 6 g ceruletide was given in steps of 2 g. Duodenal 
bile was collected in ice chilled tubes and stored at _20°C until further analysis. 
Mononuclear cells (MNCs) were isolated b~ Ficoll density centrifugation of hepari-
nized blood from one healthy individual. 10 MNCs were incubated in RPM I culture 
medium supplemented with 10% AB-serum in the presence of pre-treatment and 
post-treatment bile in a final dilution of 1 :1000 (optimal dilution determined in pre-
vious experiments). A mixture of diphtheria/tetanus toxoid was used for antigenic 
stimulation of MNC proliferation. To obtain reference values, prednisolone was 
added to the cultures in final dilutions of 10-4, 10-6 and 10-8 molll in the presence 
of bile collected at entry. Cultures without diphtheria/tetanus toxoid were used for 
° determination of background MNC ~roliferation. MNCs were incubated at 37 C in 
5% CO~atmosphere for five days; H-thymidine was added 24 hours before har-
vesting. H-thymidine incorporation was measured with a liquid scintillation counter 
and MNC proliferation was expressed as counts per minute (cpm). Phytohaemag-
glutinin was used to check the proliferative potential of the MNCs. Every culture 
was performed in triplicate. 
Statistical analysis 
Since no data on the effects of budesonide and prednisone on liver biochemistry in 
PSC patients receiving UDCA were available and because this was a pilot study, a 
statistical power analysis was not performed. A group of six patients per treatment 
arm was considered sufficient for this pilot study to get an impression of the effica-
cy of the drugs. Data were analysed according to the intention-to-treat principle. 
Mean daily VAS scores per week for pruritus and fatigue were calculated by divi-
ding the total score for one week by seven. Serum liver tests are expressed as 
multiples of the upper limit of normal (ULN). The Kruskal-Wallis test was used to 
assess overall differences between the three treatment arms. Paired t-tests were 
applied after verifying that differences between pre-treatment and post-treatment 
values exhibited an approximately normal distribution; otherwise, Wilcoxon's sig-
ned-rank test was used. A p-value 5 0.05 was considered statistically significant. 
Results 
At entry, the three groups were largely comparable in terms of clinical and bioche-
mical characteristics (table 2). The mean age was 43 years (range 26-65); 14 
patients were male and 11 (61 %) had a history of IBD. No significant differences in 
biochemical and clinical values at entry between the three groups existed. Com-
pliance was good; two patients used 88% of the study medication, all others used 
100% as indicated by pill count. 
Pruritus and fatigue 
The number of patients reporting pruritus at entry and after eight weeks was four 
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Table 2: Features at entry. 
-
Prednisone 10 mg Budesonide 9 mg Budesonide 3 mg 
n=6 n=6 n=6 
Age (years) 44.5 (10.9) 46.4 (9.7) 38.9 (12.3) 
Sex (male/female) M 6/ F 0 M 4/ F 2 M 4/ F2 
UOCA dose (mg/kg) 11.8 (2.2) 10.4 (2.2) 14.6 (6.8) 
IBO (n) 3 UC / 1 CO 2 UC/ 1 CO 4 UC/OCO 
Treatment with 
-5-ASA (n) 4 3 3 
- Rifampicin (n) 0 1 0 
Bilirubin (ULN) 1.1 (0.3) 0.9 (0.4) 0.8 (0.3) 
APh (ULN) 2.4 (0.9) 1.8(1.4) 2.8 (1.4) 
y-GT (ULN) 6.5 (5.0) 6.4 (7.9) 7.8 (6.6) 
AST (ULN) 1.2(0.4) 1.2(1.0) 1.3 (0.4) 
ALT (ULN) 2.0 (0.9) 1.7 (2.2) 1.9 (0.6) 
Albumin (ULN) 1.0 (0.3) 1.0 (0.3) 1.0 (0.2) 
IgG (ULN) 1.2 (0.7) 0.9 (0.3) 1.0 (0.3) 
Means with standard deviation in parentheses. 
IBO: inflammatory bowel disease; UC: ulcerative colitis; CO: Crohn's disease; 
5-ASA: 5-amino salicylic acid. 
Table 3: Effects of prednisone and budesonide on the pituitary-adrenal axis . 
Entry End • 11 p 
ACTH (pg/I) 
Prednisone 10 mg 48.0 (14.6) 27.5 (21.9) -40.7 (23.0) 0.130 
Budesonide 9 mg 35.8 (7.3) 21.7(9.1) -36.6 (13.4) 0.064 
Budesonide 3 mg 38.1 (13.4) 44.0 (14.5) + 19.0 (13.6) 0.219 
OHEA (~mol/I) 
Prednisone 10 mg 5.4 (2.8) 2.6 (1.0) -39.2 (15.9) 0.081 
Budesonide 9 mg 5.8 (3.3) 3.7 (3.1) -40.9 (10.4) 0.052 
Budesonide 3 mg 3.7 (1.5) 3.5 (1.4) -7.1 (8.4) 0.359 
Means with standard deviation in parentheses. 
11: percentage change from baseline with standard error of the mean in 
• 
parentheses . 
Within group comparison 
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Figure 2: The difference between pre-treatment and 8-week VAS pruritus score in 3 mg 
budesonide (bud 3 mg), 9 mg budesonide (bud 9 mg) and 10 mg prednisone 
(pred 10 mg) groups. Horizontal bars indicate medians. 
Figure 3: The difference between pre-treatment and 8-week VAS fatigue score in 3 mg 
budesonide (bud 3 mg), 9 mg budesonide (bud 9 mg) and 10 mg prednisone 
(pred 10 mg) groups. Horizontal bars indicate medians. 
and three in the 10 mg prednisone group, two and none in the 3 mg budesonide 
group and one and two in the 9 mg budesonide group, respectively. The median 
difference between baseline and 8 weeks score was +0.15 points for the 3 mg 
budesonide group, -0.1 for the 9 mg budesonide group and -1.1 for the 10 mg 
prednisone group. The median decrease from baseline in the 10 mg prednisone 
group was significantly greater compared to the other groups (both p<0.05) 
(figure 2). 
Eleven patients complained of fatigue at entry: three in the 10 mg prednisone 
group, three in the 3 mg budesonide group and five in the 9 mg budesonide group. 
After eight weeks, eight patients complained of fatigue: two in the 10 mg predni-
sone group, three in the 3 mg budesonide group and three in the 9 mg budesonide 
group. The median change from 
baseline of the fatigue score was 
similar in all groups (all 0.6) (figure 
3). 
Serum liver tests 
In the 10 mg prednisone group, the 
mean changes from baseline in APh 
(-23.4%, p=0.03; 95%-confidence 
interval (95 CI): -42.7% to -4.2%) 
(figure 4) and IgG (-16.2%, p=0.04; 
95% CI: -24.8% to -7.5%) were sig-
nificantly less than zero after eight 
weeks of treatment. The liver and 
bone APh isoenzyme fractions 
decreased by a mean of 27.6% 
(95% CI: -54.5% to -0.8%; p=0.04) 
"m.lw"',1 
Figure 4: Course of serum alkaline phos-
phatase in the 10 mg predniso-
ne, 9 mg budesonide and 3 mg 
budesonide groups. Data are 
expressed as multiples of the 
upper limit of normal (ULN). Hori-
zontal bars indicate medians. 
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and 10.0% (95% CI: -38.1 % to 
+ 18.0%; p=O.9), respectively. No sig-
nificant changes in serum liver tests 
were observed in the 3 mg budeso-
nide and 9 mg budesonide groups. 
The mean changes in APh and IgG 
in the 10 mg prednisone group, 
however, did not differ significantly 
from the changes in the 3 mg and 9 
mg budesonide groups. Serum biliru-
bin (figure 5), AST, ALT, y-GT and 
IgM did not change significantly in 
the 10 mg prednisone group. Albu-
min and prothrombin time remained 
stable in all three groups. 
Pituitary-adrenal axis 
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Figure 5: Course of serum bilirubin in the 
10 mg prednisone, 9 mg budeso-
nide and 3 mg budesonide 
groups. Data are expressed as 
multiples of the upper limit of 
normal (ULN). Horizontal bars 
indicate medians. 
Significantly greater decreases in serum ACTH were found in the 10 mg predni-
sone group (-40.7%; p=0.04) and 9 mg budesonide group (-36.6%; p=0.02) com-
pared to the 3 mg budesonide group (+19.0%)(table 3). No significant differences 
in percentage change in baseline values for DHEA between the three treatment 
arms were found. 
Adverse events 
A 42-years old male patient was diagnosed with PSC in 1991. At regular follow-up 
examinations transaminases were mildly elevated and IgG was normal. He was 
allocated to the 9 mg budesonide group; he had also taken rifampicin for pruritus in 
the preceding 6 months. When prednisone was tapered off, marked hepatitis deve-
loped: serum bilirubin 105 j.Lmol/l (normal < 17j.Lmol/l); ALT 595 lUll (normal < 30); 
IgG 23.2 gil (normal < 16). Antinuclear antibodies (titre 1 :2560), anti-DNA (> 50 
IE/ml), anti SS-A and anti SS-B antibodies tested positive. Serological markers for 
hepatitis A, Band C were negative. A liver biopsy revealed dense portal mononu-
clear infiltrates with interface hepatitis, numerous Councilman bodies and collapse 
of liver parenchyma. Combination treatment with prednisone (30 mg/day) and aza-
thioprine (50 mg/day) was instituted, resulting in rapid normalisation of serum bili-
rubin, ALT and IgG. An overlap syndrome of PSC and AIH was diagnosed. 
One patient, who received 10 mg prednisone per day, reported slightly impaired 
vision and itching of the eyes. In the 9 mg budesonide group, one patient reported 
increased facial acne and another patient complained of nausea. These side-
effects were found to be transient. No other adverse events were noted. 
Biliary corticosteroid activity 
Duodenal bile collection was successful in 15 cases; it failed in two patients of the 
9 mg budesonide group and one patient of the 3 mg budesonide group. Mean cpm 
of diphtheria/tetanus toxoid-stimulated MNCs incubated with bile collected at entry 
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with and without in vitro addition of 10-8 molll prednisolone was 11504.0 (sd 
6235.1) and 15614.6 (sd 6188.1), respectively (p=O.01). Thus, it was possible to 
measure an inhibitory effect comparable to that of prednisolone at a concentration 
of 10-8 molll, corresponding to a concentration of 10-5 molll in undiluted bile. Mean 
cpm of diphtheria/tetanus toxoid-stimulated MNCs incubated with bile collected at 
entry and at the end of the study was 15614.6 (sd 6188.1) and 15073.9 (sd 
8586.3), respectively (p=0.36). In none of the groups could an inhibitory effect of 
post-treatment bile compared with pre-treatment bile on MNC proliferation be 
demonstrated. 
Discussion 
This study indicates that in PSC patients receiving treatment with ursodeoxycholic 
acid additional therapy with 10 mg prednisone per day or 3 or 9 mg budesonide 
per day does not result in major short-term improvements in clinical and laboratory 
parameters of the disease, although treatment with 10 mg prednisone per day was 
associated with a significant decrease in pruritus as assessed by visual analogue 
scores. 
Currently, no effective medical treatment has been found for PSC. This study was 
based on the hypothesis that both immunologically mediated inflammatory activity 
(1) as well as bile acid-related liver damage contribute to the gradually progressive 
liver disease that characterises PSC. Consequently, a therapeutic approach based 
on combined treatment with ursodeoxycholic acid and low-dose immunosuppres-
sives was considered of interest. The results of this 8-week study do not allow con-
clusions as to the possible long-term effects of such a treatment regimen but they 
do seem to indicate an absence of major short-term benefits. In this context, it 
should be noted that the patients included in this study had relatively mild liver dis-
ease, as indicated by the biochemical test results at entry, which maya priori have 
limited the chance to observe significant changes in liver biochemical parameters 
upon treatment with immunosuppressives. 
Interpretation of the effect of corticosteroids on pruritus is markedly hampered by 
the considerable variation in both the number of symptomatic patients and the 
severity of pruritus among the treatment groups. Moreover, this study was not 
placebo-controlled. Therefore, the observed beneficial effect of prednisone should 
be interpreted with caution and would require confirmation in further studies. Inte-
restingly, a positive effect of corticosteroids on pruritus has also been reported for 
another cholestatic liver disease, primary biliary cirrhosis (28,29). This effect could 
be related to the reported ability of corticosteroids to induce cytochrome P450-3A 
activity (30), which is analogous to the action of the well-known antipruritic drug 
rifampicin. 
Budesonide is a potent corticosteroid with high receptor affinity. It is rapidly meta-
bolised in the liver into almost inactive metabolites (31). In theory, a high concen-
tration of active drug could be delivered to the biliary tract, whereas systemic con-
centraflons remain low. On the other hand, budesonide might be inactivated before 
exerting its immunosuppressive effect. The first hypothesis is not supported by the 
results of our experiments with duodenal bile, showing absence of increased 
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immunosuppressive action in bile of patients treated with budesonide. This study 
demonstrates that suppression of the pituitary-adrenal axis by 10 mg prednisone 
per day and 9 mg budesonide per day was comparable while 3 mg budesonide per 
day had no such effect. Although the systemic availability of budesonide is repor-
ted to be low (31,32), we, in accordance with others (19,33), found that in patients 
treated with 9 mg budesonide as well as 10 mg prednisone the pituitary-adrenal 
axis was significantly suppressed. 
In general, patients tolerated the low-dose corticosteroid regimen well. One excep-
tional serious adverse event was observed in a patient treated with 9 mg budesoni-
de per day who developed severe, corticosteroid-responsive hepatitis when corti-
costeroids were tapered off. We are not aware of any similar cases. Although the 
aetiopathogenesis of this event remains speculative, available data suggest that in 
this patient manipulation of the immune system triggered the development of an 
autoimmune-mediated liver disease. 
Relatively few studies have evaluated the effects of immunosuppressive drugs in 
PSC and the findings are inconsistent. No evidence was found for beneficial effects 
of D-penicillamine (34), cyclosporine (35), methotrexate (36,37) or combination 
therapy with colchicine and prednisone (16). Conversely, serum liver tests ap-
peared to respond favourably to treatment with tacrolimus (38) whereas some 
benefit of treatment with prednisone monotherapy has been reported for a series 
of ten patients (15). 
In conclusion, in this pilot study only minor short-term beneficial effects of treat-
ment with prednisone but not budesonide were noted in PSC. The apparent bene-
fit-risk ratio of immunomodulating agents, as assessed in this and previous stu-
dies, does not therefore support long-term evaluation of these agents in PSC. 
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Introduction 
After the initial report by Poupon et al (1), Leuschner and co-workers published the 
results of the first randomised controlled trial with ursodeoxycholic acid (UDCA) in 
primary biliary cirrhosis (PSG) in 1989 (2), Since then, numerous studies (2-12) 
(table 1) have confirmed their findings, showing beneficial effects of UDCA on liver-
biochemistry, especially on serological markers of cholestasis. However, no signifi-
cant improvements in histology are observed. In 1997, a meta-analysis combining 
data of the French, Canadian and American studies showed that UDCA significantly 
increases transplantation-free survival (13). It was concluded that UDCA should be 
considered as a safe, effective and life-extending treatment for patients with PSC. 
Although these results were encouraging, the efficacy of UDCA seems only mode-
rate because induction of complete disease remission is achieved in less than 5% 
of patients (14). Furthermore, the beneficial effects on transplantation-free survival 
are mainly observed in stage 4 of the disease (13) and UDCA has not been found 
to improve invalidating symptoms, such as pruritus and fatigue. 
In primary sclerosing cholangitis (PSG), identical results were found regarding 
serum liver function tests and histology (15-21). In 1997, results from a large 
double-blind randomised controlled study comprising 105 patients with a mean fol-
low-up of 2 years have become available; no significant differences in disease 
progression were observed in the UDCA treated group when compared with place-
bo (22). However, as in PSC, effects of UDCA on survival may only become appa-
rent after a mean follow-up of at least 4 years, and larger patient-numbers may be 
required. Currently, a Scandinavian group is performing a large randomised con-
trolled trial with a follow-up of at least 4 years, comparing UDCA with a placebo. 
The results of this trial are not yet available. 
Table 1: Major clinical trials in PBC with UDCA mono-therapy 
Results 
year design follow-up n biochemistry histology survival 
Leuschner (2) 1989 RCT 9 months 20 improved trend n.a. 
Battezzati (8) 1993 RCT 6 months 88 improved n.a. n.a. 
Po upon (6) 1994 RCT 4 years 145 improved n.a. improved 
Lindor (5) 1994 RCT 2 years 180 improved n.S. n.S. 
Heathcote (4) 1994 RCT 2 years 222 improved trend n.s. 
Turner (10) 1994 RCT 2 years 64 improved n.s. n.S. 
Combes (11) 1995 RCT 2 years 151 improved trend n.s. 
Eriksson (64) 1997 RCT 2 years 116 improved n.S. n.S. 
Poupon (13) 1997 meta 4 years 548 n.a. n.a. improved 
Improved: significantly improved; trend: improvements were reported, which were not sig-
nificant; n.a.: not assessed; n.s.: not significant. 
UDCA did not improve symptoms in any of the trials. 
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Although the exact pathogenesis of PBC and PSC is unknown, there is growing 
evidence of an autoimmune mediated aetiology (23-27). The most important 
mechanism of action of UDCA is probably its reduction of bile acid mediated 
damage (28-30), by replacing endogenous toxic hydrophobic bile salts with the 
more hydrophilic and less toxic UDCA. In view of the supposed immunogenetic 
background of PBC and PSC, the evaluation of combinations of UDCA with other 
drugs, especially immunosuppressives, seems to be a logical next step. It is the 
purpose of the final chapter of this thesis to evaluate several combination therapies 
in PBC and PSC and to discuss strategies for further studies. Furthermore, various 
prognostic markers and models of prognosis will be reviewed. 
Combination therapy in PBC 
Combination treatment of UDCA with colchicine 
The anti-fibrotic and anti-inflammatory effects of colchicine in combination with 
UDCA were assessed in several studies (31-37). Significant decreases in pruritus, 
fatigue and alkaline phosphatase (APh) and bilirubin values were found in a rando-
mised controlled trial comparing the efficacy of the combination of UDCA with col-
chicine versus a placebo (31). However, the design of this study does not allow to 
compare the efficacy of the combination of UDCA and colchicine with UDCA 
monotherapy, which is nowadays considered as the standard treatment of PBC. 
A randomised controlled trial from Japan showed significant beneficial effects of 
colchicine added to UDCA versus UDCA monotherapy on serum liver function 
tests (37). However, in 3 other randomised controlled trials assessing the efficacy 
of additional colchicine (1 mg/day) in UDCA treated PBC patients, no beneficial 
effect of colchicine on serum-transaminases, APh, bilirubin or clinical signs and 
symptoms was established (33, 35, 38). Furthermore, effects of additional colchi-
cine on histological markers were absent (33). 
Vuoristo et al (36) performed a trial comparing the efficacy of UDCA monotherapy 
with colcichine monotherapy and with a placebo. Colchicine only modestly impro-
ved liver function tests, whereas UDCA significantly improved liver-biochemistry 
when compared with colchicine and with placebo. In conclusion, all available data 
strongly suggest that added colchicine does not improve the results that can be 
achieved by UDCA treatment alone. 
Combination therapy of UDCA with methotrexate 
In 1991, Kaplan et al presented data suggesting beneficial effects of methotrexate 
in the treatment of PBC (39). Since then, several studies assessing the effects of 
additional methotrexate in UDCA-treated patients have become available (40-45). 
In 2 randomised controlled trials no additional improvement in clinical signs, symp-
toms, biochemistry and histology in patients treated with UDCAImethotrexate com-
bination therapy when compared with UDCA monotherapy were found (42, 44). In 
an open label trial, Belgian investigators showed beneficial effects of methotrexate 
monotherapy on liver biochemistry, without concomitant improvements in histology 
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(46). In the following 2-year randomised controlled trial, significant improvements in 
liver biochemistry were found in patients treated with the combination of UDCA 
and methotrexate when compared with UDCA monotherapy. However, no concur-
rent improvements in clinical and histological parameters were observed (40). In 
the Belgian study, methotrexate toxicity consisted of interstitial pneumonitis (one 
patient), a transient rise in serum transaminases at three months of follow-up (five 
patients) and of a significant decrease of blood platelets and white blood cells in 
the methotrexate group after 2 years. All investigators concluded, that in view of 
the possible side effects and the limited therapeutic value, the use of methotrexate 
cannot be recommended in PBC at present. 
Combination therapy of UDCA with corticosteroids 
The use of corticosteroids has long been considered contraindicated in PBC (47) 
because of fear of increased bone-loss (48-50). Consequently, only few studies 
examined their therapeutic potential (51-54). In 1992 Mitchison et al. were the first 
to report the results of a randomised controlled trial, evaluating prednisolone in 
PBC (51). A significant decrease in APh and immunoglobulins in the prednisolone 
group was found when compared with controls. Histological examination of paired 
liver biopsies taken at the start of the trial and after 3 years suggested a beneficial 
effect of prednisolone treatment. No deterioration in bone mass was detected. 
Leuschner et al. performed a 9-months randomised controlled trial in 30 previously 
untreated PBC patients assessing the effects of prednisolone added to UDCA ver-
sus UDCA monotherapy 52). Bone mass density remained stable in both groups. 
Serum liver function tests improved significantly in both groups, but no significant 
differences in biochemical response between both groups were observed. The 
most important finding was that liver histology improved significantly in the group 
treated with UDCA and prednisolone. By the same investigators, the effects of 
budesonide added to UDCA were evaluated with a similar study design and the 
results were identical; histology improved significantly in patients treated with 
UDCA and budesonide, whereas histological markers did not change in patients 
treated with UDCA monotherapy 55). 
In this thesis the results are presented of a 1-year multi-centre placebo controlled, 
double-blind trial to assess the effects of a combination of prednisone and aza-
thioprine in addition to UDCA, showing beneficial effects on symptoms, liver bio-
chemistry and histology. Bone mass remained stable in patients treated with elidro-
nate/calcium. Currently, strong efforts are made to start a large European multi-
centre trial assessing the long-term effects of this combination therapy on 
transplantation-free survival and to evaluate its possible side-effects, especially the 
effects on bone-mass. 
Combination therapy in PSC 
Compared to PBC, relatively few trials were performed in PSC and studies eva-
luating combination therapy are even fewer. 
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Immunosuppressive drugs 
Lindor et al. have assessed the efficacy of combination therapy with prednisone 
and colchicine in PSC (56). Twelve patients received 10 mg prednisone and 1.2 mg 
colchicine per day for a period of 24 months. Data were compared with a group of 
concurrent historic controls, which were matched with respect to age, sex, histolo-
gical stage and serum bilirubin. After 2 years of treatment no significant differences 
in biochemical tests were found between the treated group and their controls. Eva-
luation of serial biopsies showed no significant changes between both groups. In 
the untreated group, ascites developed in 4 patients, gastro-intestinal bleeding in 3 
patients and 2 patients died. In contrast, in the treated group, the combination of 
variceal bleeding and ascites occurred in only 1 patient and no deaths occurred. 
The authors concluded that these results warrant a larger randomised controlled 
trial with this medication. 
In this thesis we describe the results of a pilot-study assessing the effects of pred-
nisone or budesonide added to UDCA in PSC. Small but significant improvements 
in scores for pruritus and in APh were found in patients treated with prednisone. 
No effects of budesonide were observed. In view of a severe adverse event in one 
patient, who developed autoimmune hepatitis after the trials drugs were discon-
tinued (budesonide), and the limited benefit of the drugs, we consider further stu-
dies with this treatment regimen unattractive in PSC. 
Results of a study evaluating combination therapy with UDCA and methotrexate in 
PSC have become available in 1996 (57). Nineteen patients received 13-15 mg/kg 
UDCA per day in combination with 0.25 mg/kg methotrexate per week. A control 
group consisted of a concurrently studied but non-randomised group of patients 
receiving UDCA monotherapy and was matched for age, sex, serum liver function 
tests and histological stage. In the patients receiving combination therapy, no chan-
ges in scores for fatigue and pruritus occurred. No significant difference in bioche-
mical response between patients receiving UDCA monotherapy or the combination 
of UDCA and methotrexate was observed. After the withdrawal of methotrexate no 
changes in serum liver function tests occurred. Histological changes in the group 
with combination therapy were as follows: 2 patients progressed, 6 remained the 
same and 4 improved. There was a considerable number of drop-outs: 3 were 
referred for transplantation, 1 died from a carcinoma of the small bowel, 1 withdrew 
voluntarily, 3 patients were withdrawn from the study because of hair-loss and 2 
because of sever pulmonary problems requiring hospitalisation. The authors con-
clude that the combination of UDCA and methotrexate offers little benefit over 
UDCA monotherapy, whereas substantial side-effects occur. Considering the 
results of all trials with immuno-suppressive drugs in PSC, the addition of an 
immunosuppressant to UDCA therapy becomes less and less attractive. 
Endoscopic intervention therapy 
The combination of UDCA with endoscopic intervention therapy could be promi-
sing. Stiehl and co-workers performed an 8-year prospective study in 65 patients, 
evaluating the efficacy of UDCA in combination with endoscopic dilatation of major 
bile duct stenoses (58). In all patients, enodoscopic retrograde cholangiography 
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(ERG) was performed at entry. In patients without narrowing of the common bile 
duct, repeat ERG was performed with 2-year intervals and whenever serum liver 
function tests deteriorated with at least 20%. In patients with major bile duct steno-
ses, endoscopic sphincterotomy of the papilla and rigid dilatation and subsequent 
balloon dilatation was performed until opening of the stenosis, assessed by repeat 
ERG. If necessary, a biliary stent was placed. In 23 patients with major duct-steno-
ses, 91 endoscopic dilatations were needed to obtain opening of the stenoses. In 5 
patients intermittent stenting was performed. Pancreatitis occurred after 7 proce-
dures, bacterial cholangitis after 3 procedures and perforation of the common bile 
duct occurred once. No patients died because of the procedure. It appeared that 
the actuarial survival in both the total group (p=0.001) and in the subgroup of 
patients who had undergone endoscopic intervention (p=0.006) was much better 
than predicted survival. Finally, the Amsterdam group has reported that short-term 
stent placement of only 9 days leads to the same results as leaving the stent in situ 
for 2 to 3 months, and greatly reduces the associated complications of stent clog-
ging and cholangitis (59). 
Biochemical remission 
Since PBG and PSG are both diseases with a slow progression, trials - which 
investigate the potential of a drug to improve survival - need to include large 
patient numbers and a long follow-up period. In PBG, a number of easy to deter-
mine surrogate markers to predict the effects of medical intervention have therefor 
been used such as serum transaminases, bilirubin, histological markers and bio-
chemical remission. Based on a multiple regression analysis of a large cohort of 
PBG patients, serum bilirubin, serum albumin, prothrombin time, age and the pre-
sence or absence of oedema were combined in the Mayo model for the prediction 
of prognosis of PBG. This model has the advantage of not requiring a liver biopsy 
60). 
In the Dutch cohort of PBG patients treated with UDGA, bilirubin, albumin, aspar-
tate amino transaminase, normalisation of bilirubin, biochemical remission and bili-
rubin during follow-up were found to be of predictive significance for both treatment 
failure and death in an univariate model. In a multivariate model, including all be-
fore-mentioned variables, it appeared that only bilirubin at entry or during follow-up 
and age were significant prognostic factors of death and transplantation. Bilirubin 
at entry or during follow-up together with the presence of cirrhosis significantly pre-
dicted treatment failure (multivariate model). 
Although serum bilirubin, age, histological stage, presence or absence of inflam-
matory bowel disease, hepatomegaly and splenomegaly (61-63) have been found 
to be associated with survival, the Mayo model for the prediction of prognosis in 
PSG only includes age, serum bilirubin, albumin, aspartate amino transaminase 
and the presence or absence of variceal bleeding. The predictive value of bioche-
mical remission in PSG has not been evaluated. 
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Conclusions 
UDCA has now been established as an effective medical treatment for PBC, al-
though its effects are modest. The first large randomised trial, assessing the effects 
of UDCA in PSC did not show a favourable effect of UDCA on disease progres-
sion. Other studies with UDCA in PSC are currently being performed but results 
are not yet available. In PBC, available data indicate that combination therapy of 
UDCA and methotrexate is not more effective than treatment with UDCA alone, 
whereas the side effects of methotrexate can be severe. The addition of colchicine 
did not improve the effects of UDCA monotherapy. The results obtained with corti-
costeroids either given as monotherapy or in combination with UDCA are promi-
sing. In this thesis, we show that triple therapy with UDCA and low dose predni-
sone and azathioprine was clearly superior to UDCA monotherapy. The addition of 
a bisphosphonate to this triple regimen may be bone-protective. 
Further studies are needed to establish the long term benefit-risk ratio of combined 
bile acid and immunosuppressive treatment, as well as the effects of bisphospho-
nates on bone-mass. To obtain a sample size that is large enough a joint initiative 
of several centres in Europe is currently initiating such a trial in PBC. 
In PSC, results of various trials were disappointing and there are less therapeutic 
options. Endoscopic stenting and dilation of bile-duct strictures, may be important 
to alleviate symptoms and to potentiate the effects of medical treatment. 
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SUMMARY 
In Rotterdam, the pathofysiology of cholestatic liver diseases has been investiga-
ted since 1976. This is the second thesis in which the results are presented of 
research that was performed within the framework of the Dutch Multi-Centre PBC 
Study Group and the Belgium-Dutch Multi-Centre PSC Study Group. 
Chapter 1 
In this chapter an overview is given of the scientific knowledge about cholestatic 
liver diseases at the time that the work on this thesis began. The pathofysiology of 
primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSG) is descri-
bed as well as the biochemical and histological characteristics of both diseases. 
An overview is given of the effects of various drugs that were evaluated in random i-
sed controlled trials. Especially the treatment of PBC with ursodeoxycholic acid 
(UDCA) seemed promising at that time; no effective medical treatment for PSC 
was available. Finally, the aims of this thesis are described. 
Chapter 2 
In 1997 a study was reported, combining individual data from three large randomi-
sed controlled trials, confirming that UDCA significantly improves transplantation-
free survival in PBC. However, it was debated whether prognostic factors, which 
changed as a result of the use of UDCA (especially serum bilirubin), could still be 
used. After analysis of 203 PBC patients that were followed within the framework of 
the Dutch Multi-Centre PBC Study Group, it appeared that serum bilirubin remains 
the strongest independent prognostic factor both before and during treatment with 
UDCA. 
In autoimmune hepatitis (AI H), biochemical remission, defined as the simultaneous 
normalisation of serum bilirubin and aspartate amino transaminase (AST) and 
alkaline phosphatase (APh) ~ 1.5 x upper limit of normal (ULN), serves as a prog-
nostic factor. In our cohort of PBC patients, biochemical remission was significantly 
associated with a better prognosis (univariate); this association was not found in a 
multi-variate analysis. 
Except for serum bilirubin that slightly increased after 4 years of treatment all other 
serum liver function tests remained stable at their improved levels, indicating a gra-
dual progression of the disease. 
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Chapter 3 
The dose of UDCA, which has been applied in various trials assessing the effects 
of UDCA in PBC, ranges from 7.7 mg/kg/day to 15 mg/kg/day. The protocol of the 
Dutch Multi-Centre PBC Study Group dictates a dose of 10 mg/kg/day. It was 
hypothesised that a higher dose of UDCA would lead to a higher biliary enrich-
ment, whereby the effectiveness of UDCA would increase. Therefore, a 6-months 
randomised controlled trial assessing the effects of UDCA 10 mg/kg/day versus 20 
mg/kg/day was initiated. The higher dose was well tolerated. Patients, who were 
treated with the higher dose, achieved significant additional improvements in 
serum liver function tests. However, no Changes in serum bilirubin occurred in both 
groups. There was a significant increase of the percentage of UDCA in the bile 
acid pool. A UDCA dose of 13-15 mg/kg/day seems to be the preferred dose. 
Chapter 4 
The main mechanism of action of UDCA is to reduce liver cell damage caused by 
cholestasis. The autoimmune process that is present in PBC is not influenced by 
UDCA. Thus, additional beneficial effects may be achieved by adding an immuno-
suppressive drug to the treatment with UDCA. In chapter 4, we report the findings 
of a 1-year double blind randomised controlled trial in 50 PBC patients, who were 
treated with prednisone and azathioprine in addition to UDCA. In patients treated 
with prednisone and azathioprine, significant improvements were found in the 
score for pruritus and in biochemical markers for cholestasis, liver cell damage, 
immune activity and fibrogenesis when compared with placebo (UDCA mono-the-
rapy). Histological scores for disease activity and disease stage improved signifi-
cantly in the group treated with prednisone and azathioprine, whereas these chan-
ges were absent in the placebo-group. Treatment with cyclic etidronate and 
calcium protected against corticosteroid induced bone-loss (not in this thesis). 
Chapter 5 
The long-term effects of UDCA on biochemical, histological and cholangiographic 
characteristics of PSC patients were not well described, when the study, described 
in chapter 5, was initiated. Previously our group had shown that biliary enrichment 
with UDCA and the effects on serum liver function tests was independent of the 
dose scheme. Others however suggested differently. 
After treatment with UDCA for 2 years of 48 PSC-patients according to the protocol 
of the Dutch Multi-Centre PSC Study Group, no changes in symptoms, histology, 
or cholangiographic findings were observed. Biochemical parameters of cholesta-
sis and liver cell necrosis significantly improved. Serum bilirubin remained stable. 
UDCA was well tolerated. Actuarial transplantation-free survival was 91 % at 2 
years and did not differ significantly from predicted survival in untreated patients 
(MAYO model). No significant differences in any of the study endpoints (symptoms, 
serum liver function tests, cholangiographic findings, histology, disease progres-
sion) were found between patients who took the UDCA as a single bed-time dose 
or divided during the day (randomised controlled study design). 
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Chapter 6 
An overlap syndrome between PSG and AIH has been described previously. In 
PSG, a similar syndrome might be found. In chapter 6, we describe the biochemi-
cal, histological and cholangiographic features of 8 patients who were diagnosed 
with both PSG and AIH. Initially, all patients responded well to treatment with corti-
costeroids. However, two patients needed a liver transplantation. The overlap syn-
drome of PSG and AIH might be more common than hitherto assumed. The true 
incidence, however, is unknown. 
Chapter 7 
As the short-term beneficial effects of corticosteroids added to UDGA became 
apparent in PSG patients, a pilot-studY with a similar treatment regimen in PSG 
patients was initiated. In chapter 7, the results of an 8-week double-blind randomi-
sed pilot study in 18 patients assessing the effects of prednisone (10 mg/day) or 
budesonide (3 mg/day or 9 mg/day) added to UDGA (12 mg/kg/day) are reported. 
No effects of treatment with budesonide were found. APh, immunoglobulin G (lgG) 
and score for pruritus significantly improved in patients, who were treated with 
prednisone. After the medication was discontinued, a serious adverse event 
(autoimmune hepatitis) was observed in one patient who was treated with 9 mg 
budesonide. The empirical use of corticosteroids in PSG can not be recommended. 
Chapter 8 
It is now clear that treatment of cholestatic liver diseases with UDGA has limited 
potential and additional medical treatment is needed. In chapter 8, an overview of 
studies is given that were performed to assess the effects of combination therapy. 
In PSG, a combination of UDGA with immunosuppressives seems promising. In 
PSG, less therapeutic options are available although endoscopic procedures in 
combination with UDGA could prove to be valuable. Finally, the use of prognostic 
factors, especially biochemical remission, is discussed. 
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SAMENVATTING 
In Rotterdam wordt sedert 1976 onderzoek verricht naar de klinische vormen en 
behandeling van cholestatische leverziekten. Dit proefschrift is het tweede met de 
resultaten van onderzoek dat werd uitgevoerd in het kader van de Dutch Multi-
Centre PBC Study Group en de Belgium-Dutch Multi-Centre PSC Study Group. 
Hoofdstuk 1 
In dit hoofdstuk wordt een overzicht gegeven van de kennis over cholestatische 
leverziekten op het moment dat met het werk aan dit proefschrift werd begonnen. 
Er wordt ingegaan op de pathofysiologie van primaire biliaire cirrose (PBC) en pri-
maire scleroserende cholangitis (PSC) en op de biochemische en histologische 
kenmerken van be ide ziektebeelden. Er wordt een overzicht gegeven van de effec-
ten van verschillende geneesmiddelen die bij beide ziektebeelden in gerandomi-
seerde studies zijn bestudeerd. Vooral de behandeling van PBC met ursodeoxy-
cholzuur (UDCA) leek destijds veelbelovend; er was echter geen effectieve 
medicamenteuze therapie voor PSC. Tenslotte worden de doelen van dit proef-
schrift uiteengezet. 
Hoofdstuk 2 
In 1997 werden de resultaten gepubliceerd van een studie, waarin de individuele 
data van 3 grote studies werden gecombineerd, die de gunstige effecten van 
UDCA op de transplantatie vrije overleving van patiemten met PBC bevestigden. 
Het was echter onduidelijk of prognostische factoren, die door het gebruik van 
UDCA in waarde veranderden (m.n. serum bilirubine), nog als zodanig mochten 
worden gebruikt. Na analyse van het cohort patienten (n=203) dat werd gevolgd in 
het kader van de Nederlandse Multicentrische PBC studiegroep bleek dat biliru-
bine zowel voor aanvang van behandeling met UDCA als tijdens deze behandeling 
de sterkste onafhankelijke prognostische factor bleef. 
Bovendien werd onderzocht of, naar analogie van auto-imuun hepatitis, biochemi-
sche remissie, gedefinieerd als het gelijktijdig optreden van een normaal bilirubine, 
aspartaat amino transaminase (AST) en alkalische fosfatase (APh) :;; 1.5 x boven-
grens van normaal (ULN), als prognostische factor zou kunnen dienen. Alhoewel 
biochemische remissie significant geassocieerd was met een betere prognose 
(univariaat) verdween deze associatie in een multivariate analyse. 
Aile biochemische leverfunctietesten bleven op een stabiel verbeterd niveau, 
behalve serum bilirubine dat een lichte stijging vertoonde na 4 jaar behandeling 
met UDCA, hetgeen wijst op een langzame progressie van de ziekte. 
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Hoofdstuk 3 
De dosering UDCA, die in verschillende studies naar de effecten van UDCA in 
PBC werd gebruikt loopt uiteen van 7.7 mg/kg/dag tot 15 mg/kg/dag. Het protocol 
van de Dutch Multi-Centre PBC Study Group schreef een dose ring van 10 
mg/kg/dag v~~r. Gepostuleerd werd dat een hogere dose ring UDCA zou leiden tot 
een hogere concentratie in de gal, waardoor de effectiviteit zou toenemen. Daarom 
werden in een gerandomiseerde studie de effecten van 2 doseringen UDCA (10 
mg/kg/dag versus 20 mg/kg/dag) gedurende 6 maanden met elkaar vergeleken. 
De hogere dosering werd goed verdragen. De patienten die met de hogere dose-
ring werden behandeld verkregen significante additionele biochemische verbete-
ringen. Het bilirubine bleef gelijk. Er was een significante stijging van het percenta-
ge UDCA in de gal. De optimale dose ring voor UDCA lijkt 13-15 mg/kg/dag te zijn. 
Hoofdstuk 4 
Het voornaamste werkingsmechanisme van UDCA is het verminderen van lever-
schade die optreedt door cholestase. Het bij PBC aanwezige auto-immuun proces 
lijkt niet door UDCA te worden be·invloed. Het toevoegen van immuunsuppressief 
geneesmiddel aan de behandeling met UDCA, zou dus kunnen leiden tot additio-
nele gunstige effecten. In hoofdstuk 4 rapporteren wij de resultaten van een 1-jari-
ge dubbelblinde gerandomiseerde studie bij 50 patienten met PBC, die werden 
behandeld met prednison en azathioprine toegevoegd aan UDCA. Vergeleken met 
de placebo behandelde groep werden significante verbeteringen gevonden v~~r 
jeukscore en biochemische markers voor cholestase, levercelschade, immuunacti-
viteit en fibrogenese. Histologische scores voor ziekte activiteit en stadium toonden 
significante verbeteringen in de groep die werd behandeld met de combinatie van 
prednison en azathioprine en niet in de placebo behandelde groep. In een reeds 
eerder gepubliceerde studie (niet in dit proefschrift) werd het botbeschermende 
effect van behandeling met cyclisch etidronaat en calcium bij de patienten die wer-
den behandeld met prednison beschreven. 
Hoofdstuk 5 
De langetermijnseffecten op biochemische, histologische en cholangiographische 
kenmerken van PSC patienten, die worden behandeld met UDCA waren bij aan-
yang van de stud ie, die wordt beschreven in hoofdstuk 6, niet uitvoerig bekend. 
Hoewel eerder onderzoek door onze groep had aangetoond dat de verrijking van 
de gal met UDCA en de biochemische effecten onafhankelijk waren van het dose-
ringsschema, hadden anderen verondersteld dat dit wei het geval was. Na 2 jaar 
behandeling met UDCA van 48 PSC patienten volgens het protocol van de Neder-
landse Multicentrische PSC studiegroep werden geen veranderingen in klachten, 
histologische indices of bevindingen tijdens endoscopische retrograde cholangio-
pancreaticografie (ERCP) gevonden. Biochemische parameters v~~r cholestase 
en levercelverval verbeterden significant. Serum bilirubine bleef gelijk. UDCA werd 
goed verdragen. De 2-jaars transplantatievrije overleving was 91 % en verschilde 
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niet significant van de voorspelde overleving voor on behan del de patienten (MAYO 
model). Er was geen enkel verschil in eindpunten (klachten, lever biochemie, 
bevindingen bij ERGP, histologie, ziekte progressie) tussen patienten die de UDGA 
in een enkele dosis innamen of verdeeld over de dag (getest in een gerandomi-
seerde studieopzet). 
Hoofdstuk 6 
Sij patienten met PSG is er een overlapbeeld met auto-immuun hepatitis (AIH) 
beschreven. Ook bij PSG lijkt een dergelijk beeld te bestaan. In hoofdstuk 6 
beschrijven wij de biochemische, histologische en cholangiographische kenmerken 
van 8 patienten, bij wie zowel de diagnose PSG als AIH gesteld kon worden. Aile 
patienten reageerden initieel goed op therapie met corticostero'iden. Twee patien-
ten echter, ondergingen een levertransplantatie. Het overlapbeeld van PSG en AI H 
is een reele klinische variant waarvan de ware incidentie nog onbekend is, maar 
die minder zeldzaam lijkt dan tot nu toe werd aangenomen. 
Hoofdstuk 7 
Na de hoopgevende resultaten, die werden bereikt met corticostero'iden toege-
voegd aan UDCA bij patienten met PSC, werd een pilot-study met een dergelijk 
behandelmethode bij patienten met PSC uitgevoerd. In hoofdstuk 7 worden de 
resultaten gerapporteerd van een 8-weekse dubbelblinde gerandomiseerde studie 
met prednison (10 mg/dag) of budesonide (3 mg/dag of 9 mg/dag) toegevoegd aan 
UDCA (12 mg/kg/dag) bij 18 patienten met PSC. Sehandeling met budesonide had 
geen effect. De jeukscore, het alkalische fosfatase en immunoglobuline G (lgG) 
daalden significant in de groep die werd behandeld met prednison. Na het staken 
van de therapie trad er een ernstige bijwerking in de vorm van AIH op bij een van 
de patienten die werd behandeld met 9 mg budesonide. Terughoudendheid in het 
gebruik van corticostero'iden bij PSG lijkt derhalve op zijn plaats. 
Hoofdstuk 8 
Na de scherpere vaststelling van de effecten van UDCA in de behandeling van 
cholestatische leverziekten is nu duidelijk dat aanvullende therapeutische mogelijk-
heden noodzakelijk zijn. In hoofdstuk 8 wordt een overzicht gegeven van de stu-
dies die verricht zijn met verschillende therapeutische combinaties. Sij PSC lijkt 
een combinatie van immuunsuppressiva met UDCA veelbelovend. Sij PSC zijn de 
medicamenteuze opties beperkler maar lijkl endoscopische therapie in combinatie 
met UDGA een belangrijke aanwinst. Tenslotte worden verschillende prognostische 
factoren, m.n. biochemische remissie besproken. 
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roker, die van alcohol aileen maar misselijk word!. Ik zal je altijd dankbaar blijven 
voor je brede rug waarachter ik mocht schuilen, je luisterend oor, en voor je einde-
loze geduld in het corrigeren van mijn werk. 
Samen met Frank Vleggaar heb ik het laatste jaar zorggedragen voor de studies 
en hij zal de vaandel verder dragen. Ik denk met veel plezier terug aan onze lange 
autoritten, soms zeer vroeg in de morgen (of eigenlijk nacht) op weg naar weer 
een ziekenhuis voor patient-inclusie en dataverzameling. Het door ons samen v~~r 
aile collegae bereide kerstdiner was een groot succes. 
De dames van het trialsecretariaat dank ik bijzonder voor de adequate en precieze 
wijze waarop allerlei formulieren werden ontwikkeld, waarna de verzamelde infor-
matie feilloos in de computer werd ingevoerd. Marcelle Rensink was in het bijzon-
der bij de studies betrokken en nam steeds meer administratief werk over, waar-
voor mijn hartelijke dank. Sylvia de Vlaming droeg zorg voor de uiteindelijke 
correctie en lay-out van de manuscripten en was altijd be reid tot ver na kantoortijd 
mij terzijde te staan. Jan Boot zorgde dat aile computersystemen goed werkten en 
eventuele problemen snel werden opgelos!. De computer werd mede door hem tot 
een belangrijk "maatje" in het schrijven van dit proefschrift maar heeft niet echt 
geleid tot een "paperless office". 
De statistici Wim Hop en Bettine Hansen wil ik bijzonder danken voor hun engelen-
geduld bij de statistische begeleiding van de verschillende projecten en hun niet 
aflatende moeite om mij te behoeden v~~r de immer aanwezige statistische valkui-
len. Tijdens het "peer-review" proces van onze manuscripten is nooit commentaar 
geweest op de gevolgde statistische methoden! 
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Ik ben van mening dat een belangrijk deel van mijn plezier in mijn werk tot stand 
komt door het contact met collegae, hetgeen de afgelopen periode keer op keer 
werd bevestigd. Jullie zijn allemaal vrienden geworden, waarvoor mijn dank. 
De lekkere hapjes, die TOrkan Terkivatan mee nam tijdens het werk aan ons manu-
script hebben zeker bijgedragen aan de totstandkoming hiervan. Kom nog een 
langs! 
De inzet van dr. Johan Nix, expert op het gebied van cholangiografie, om de beoor-
deling van de ERCP's voor de PSC -studie tot een goed einde te brengen, was van 
uitzonderlijk belang voor het welslagen van de studie. Helaas is hij veel te vroeg 
overleden en mag hij de totstandkoming van dit proefschrift niet meer meemaken. 
Prof dr Fibo JW ten Kate en zijn medewerkers, in het bijzonder Hilde Kuiper, dank 
ik voor al hun inspanningen om een groot aantal leverbiopten op tijd te beoordelen. 
De leden van de "kleine" en "grote" promotie commissie dank ik hartelijk voor hun 
tijd en moeite om mijn promotie mogelijk te maken. 
De firma's (in alfabetische volgorde) Falk Pharma, Tramedico en Zambon Neder-
land hebben ruimschoots bijgedragen aan de totstandkoming van dit boekje. Hier-
voor en voor aile andere hulp tijdens het werk aan het proefschrift mijn oprechte 
dank. Ook de overige sponsors dank ik voor hun bijdrage. 
Dit proefschrift is opgedragen aan mijn grootmoeder, geboren in 1905. Haar steun 
aan ons gezin tijdens mijn langdurige opname in het Sophia Kinderziekenhuis is 
van onschatbare waarde geweest. Tijdens haar bezoekjes in het ziekenhuis waarin 
ze heel rustig over de dageJijkse dingen praatte en wat in de krant las, is onze 
band gegroeid. Ik ben ervan overtuigd dat mijn ouders, broers en ik mede door 
haar steun zo goed door die tijd zijn heen gekomen, waardoor uiteindeJijk mijn stu-
die geneeskunde mogelijk werd en dit proefschrift kon worden geschreven. 
SPONSORING 
Mijn dank gaat uit naar de diverse firma's (in alfabetische volgorde) die hebben 
bijgedragen aan de kosten van dit proefschrift. 
Hoofdsponsors: 
Falk Pharma GmbH 
Tramedico B.V. 
Zambon Nederland B.V. 
Overige sponsors: 
Boehringer Ingelheim B.V. 
Merck Sharp & Dohme B.V. 
Norgine B.V. 
Pentax Benelux B.V. 
Parke-Davis B.V. 
Roche Nederland B.V. 
Servier Nederland B. V. 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd op 14 februari 1967 geboren te Rotterdam. Zijn 
gymnasium-B diploma behaalde hij in 1985 aan Coriovallum College in Heerlen, 
waarna hij startte met de studie geneeskunde aan de Erasmus Universiteit Rotter-
dam. De Hippocratische eed legde hij af in 1993. Naast zijn studie was hij actief als 
medewerker in het studenten-verpleegteam van het Sophia Kinderziekenhuis en 
was hij bestuurslid van diverse jongerenorganisaties. Alhoewel hij tijdens zijn stu-
die enkele malen in de tropen verbleef (Zaire, Brazilie en Ghana), koos hij v~~r 
een loopbaan in Nederland, die startte als assistent-geneeskundige in het Reinier 
de Graaf Gasthuis te Delft. Vanaf december 1994 was hij gedurende 3 jaar verbon-
den als arts-onderzoeker aan de sectie hepatologie van de afdeling maag-, darm-
en leverziekten van het Academisch Ziekenhuis Rotterdam. Hij was verantwoorde-
Iijk voor de studies die werden verricht in het kader van de Nederlandse Multicen-
trische PBC Studie Groep en Belgisch Nederlandse Multicentrische PSC Studie 
Groep. De wetenschappelijke resultaten van dit werk worden weergegeven in dit 
proefschrift dat tot stand kwam onder leiding van prof dr SW Schalm, prof dr GP 
van Berge Henegouwen en drs HR van Buuren. 
Sinds maart 1998 is hij in opleiding tot internist in het Albert Schweitzer Zieken-
huis, locatie Dordwijk te Dordrecht (opleider dr J van der Meulen). 
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